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ABSTRACT OF DISSERTATION 
   
INVESTIGATING STRUCTURE AND PROTEIN-PROTEIN INTERACTIONS OF 
KEY POST-TYPE II PKS TAILORING ENZYMES  
 Type II polyketide synthase (PKS) produced natural products have proven to be an 
excellent source of pharmacologically relevant molecules due to their rich biological 
activities and chemical scaffolds. Type II-PKS manufactured polyketides share similar 
polycyclic aromatic backbones leaving their diversity to stem from various chemical 
additions and alterations facilitated by post-PKS tailoring enzymes. Evidence suggests 
that post-PKS tailoring enzymes form complexes in order to facilitate the highly 
orchestrated process of biosynthesis. Thus, protein-protein interactions between these 
enzymes must play crucial roles in their structures and functions. Despite the importance 
of these interactions little has been done to study them. In the mithramycin (MTM) 
biosynthetic pathway the Baeyer−Villiger monooxygenase (BVMO) MtmOIV and the 
ketoreductase MtmW form one such enzyme pair that catalyze the final two steps en 
route to the final product. MtmOIV oxidatively cleaves the fourth ring of the 
mithramycin intermediate premithramycin B (PreB) via a Baeyer−Villiger reaction, 
generating MTM’s characteristic tricyclic aglycone core and highly functionalized pentyl 
side chain at position 3. This Baeyer−Villiger reaction precedes spontaneous lactone ring 
opening, decarboxylation, and the final step of MTM biosynthesis, a reduction of the 4′-
keto group catalyzed by the ketoreductase MtmW.  
 Another example of co-dependent post-PKS tailoring enzymes from the gilvocarcin 
biosynthetic pathway is composed of GilM and GilR. These two enzymes form an 
unusual synergistic tailoring enzyme pair that does not function sequentially. GilM 
exhibits dual functionality by catalyzing the reduction of a quinone intermediate to a 
hydroquinone and stabilizes O-methylation and hemiacetal formation. GilM mediates its 
reductive catalysis through the aid of GilR that provides its covalently bound FADH(2) 
for the GilM reaction, through which FAD is regenerated for the next catalytic cycle. A 
few steps later, following glycosylation related events unique to each gilvocarcin 
derivative, GilR dehydrogenates the hemiacetal moiety created by GilM to establish the 
formation of a lactone and the final gilvocarcin chromophore. To achieve a better 
understanding of post-type II PKS tailoring enzymes and their protein-protein 
interactions for the benefit of future combinatorial biosynthetic efforts two specific aims 
were devised.	  	  
Specific aim 1 was to investigate the structure of MtmOIV and the role of active site 
residues in its catalytic mechanism.  
Specific aim 2 was to integrate the function of GilM and its protein-protein interactions 
with GilR that lead to their synergistic activity and sharing of GilR’s bicovalently bound 
FAD moiety.  
KEYWORDS:  Mithramycin, Baeyer-Villiger monooxygenase, O-methyltransferase, 
Gilvocarcin 
Theresa Downey 
2014 
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  TO	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  DK.	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  MTMW	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  (B)	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  OVERALL	  STRUCTURES	  OF	  MTMOIV	  AND	  THE	  MTMOIV-­‐PREMITHRAMYCIN	  B	  COMPLEX.	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PREMITHRAMYCIN	  B	  IN	  BALL	  AND	  STICK	  REPRESENTATION.	  FOR	  BOTH	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  IN	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  DENSITY	  (GREEN)	  CONTOURED	  AT	  2.5	  Σ	  FOR	  NADPH	  THAT	  WAS	  OBSERVED	  ONLY	  IN	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  23.	  NADPH	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  PUTATIVE	  NADPH	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  IN	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  NADPH	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  THE	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  TRANSPARENT	  SURFACES,	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  TO	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PARTICIPATE	  IN	  BINDING	  NADPH	  (BALL	  AND	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  WAS	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  ALL	  KNOWN	  STRUCTURES	  OF	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1 Introduction to Bifunctional and Co-dependent Post-PKS Tailoring Enzymes: The 
New Frontier of Polyketide Biosynthesis 
Natural products have proven an excellent and limitless source for drug discovery. 
In particular polyketides are well suited for drug discovery applications due to their rich 
chemical scaffolds and diverse biological activities. This broad group of natural products 
is characterized by their method of biosynthesis consisting of multiple decarboxlative 
Claisen condensations of malonyl-CoA derived extender units by a group of enzymes 
collectively known as polyketide synthases (PKSs). Bacterial polyketides can be further 
categorized into type I, type II, or type III PKS derived compounds based on the type of 
PKS responsible for their biosynthesis. Type I PKSs are non-iterative large highly 
modular proteins with multiple acyl carrier proteins (ACPs) passing along the growing 
polyketide. Type II PKSs are composed of aggregates of iteratively acting 
monofunctional proteins in which one ACP carriers the growing polyketide chain. Type 
III PKSs are much less complex ketosynthase homodimers that preform only a few 
elongation steps, adding CoA-activated building blocks to non-polyketide starter units 
(figure 1). Once the polyketide backbone has been synthesized they are diversified 
through a plethora of possible post-PKS tailoring events most commonly including 
glycosylations, oxygenations, reductions, cyclizations, aromatizations, methylations, and 
epimerizations (figure 1). The events carried out by post-PKS tailoring enzymes are 
responsible for the majority of the diversity in chemical structure seen within the 
polyketide family. Prior to these tailoring events it is rare that unaltered parent scaffolds 
produced directly from a PKS have any biological activity. Thus, post-PKS tailoring 
enzyme modifications can drastically impact a compounds chemical and biological 
properties making them lucrative targets for combinatorial biosynthetic efforts in the 
search for new medically relevant molecules. Contrary to the previously recognized 
belief that post-PKS enzymes are single function free floating cytosolic proteins it has 
become increasingly evident that many post-PKS tailoring enzymes exhibit remarkable 
multi-functionality or function as part of a multi-enzyme complex or at least a co-
dependent enzyme pair. Thus, protein-protein interactions between these enzymes must 
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play crucial roles in their structures and functions. Despite the importance of these 
interactions little has been done to study them. If fact, many researchers do not 
immediately recognize that they are dealing with a multifunctional or co-dependent 
enzyme. Although countless reviews have been published on specific polyketides, 
polyketide tailoring enzymes, and polyketide synthases themselves this review is the first 
to focus on particularly interesting examples of post-PKS tailoring enzyme 
interdependence and bifunctionality spanning the literature from 2002-2014. This 
review’s purpose is to function as source of enlightenment for those who unknowingly 
may be working with such complex enzyme systems and as a source of inspiration for 
what needs to be done in future research of post-PKS tailoring enzymes to utilize these 
systems for combinatorial biosynthetic applications.  
 
 
Figure 1. Types and mechanisms of polyketide synthases and common post-
PKS modifications.  
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1.2 Bifunctional Post-PKS Tailoring Enzymes 
 Bifunctional post-PKS tailoring enzymes have been recognized in the 
literature as far back as 1992.1 Generally speaking bifunctional post-PKS tailoring 
enzymes can exhibit two completely unique functionalities carried out by distinct 
domains or they can preform similar functionalities on different natural substrates 
within the same biosynthetic pathway. For the purpose of this discussion these 
multifunctional enzymes can be grouped into two major categories: Iteratively 
functioning and non-iteratively functioning.  
1.2.1 Iteratively Functioning Post-PKS Bifunctional Tailoring Enzymes 
Iteratively functioning post-PKS bifunctional tailoring enzymes can be defined 
as post-PKS tailoring enzymes that function multiple times consecutively within the 
same biosynthetic pathway.  
1.2.1.1 AknOx 
Aclacinomycin (Acl) oxidoreductase (AknOx) catalyzes the final two steps of 
A 
B 
Figure 2. (A) Proposed mechanism of AknOx. (B) Overall structure of AknOx 
homodimer. FAD is shown in yellow and the product AclY is shown in black in 
the right monomer.  
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Acl group polyketide antibiotic biosynthesis in which a terminal sugar moiety is 
oxidized from rhodinose to L-aculose. AknOx is a secreted flavin dependent enzyme 
that was first purified from Streptomyces galilaes MA144-M1 (ATCC31133).2 What 
is interesting about this enzyme is that it utilizes different residues within the same 
active site to catalyze two consecutive FAD-dependent reactions using the same 
bicovalently bound cofactor (figure 2A). The X-ray crystal structure (PDB 2IPI) 
reveals AknOx to have two distinct structural domains, the FAD binding F domain 
and the substrate binding S domain. The F domain consists of two α + β subdomains 
while the S domain is composed of a seven-stranded antiparallel β-sheets flanked on 
one side by four α-helices (figure 2B). During its catalytic mechanism (figure 2A) 
AknOx first converts the rhodinose sugar of AclN to cinerulouse by oxidizing the 
hydroxyl group at position C-4 to a keto group yielding AclA. It is theorized based on 
structural and site directed mutagenic studies that residue Tyr-450 removes a proton 
from rhodinose’s C-4 hydroxyl group. This proton is then transferred to the solvent 
via a proton transfer system that includes residue Tyr-144. Simultaneously, hydride 
transfer from the same C-4 position of the sugar moiety to the N-5 position of FAD 
facilitates formation of the C-4 keto group yielding the cinerulose-containing product 
AclA. The FAD moiety is reoxidized via molecular oxygen and is then ready to 
perform its oxidative role in the next reaction. AknOx’s second functionality converts 
the AclA’s cinerulose sugar to L-aculose and yields AclY as a final product (figure 
2A). To facilitate this catalytic functionality it is hypothesized again based on 
structural and site directed mutagenic studies that residue Tyr-378 initiates this 
second reaction by abstracting a proton from position C-3 of cinerulose, which is then 
transferred to the solvent by a relay system including residues Ser-376 and Glu-374. 
Next, hydride transfer from position C-2 of the carbohydrate to N-5 of FAD results in 
the C—C double bond formation that produces L-aculose and thus creates the final 
product AclY.3 
1.2.1.2 AurH 
The cytochrome P450 monooxygenase AurH from the aureothin biosynthetic 
5	  
pathway is responsible for furan ring formation via two consecutive C—O bond 
formations (figure 3A). Based on bioinformatic analysis AurH only contains a single 
heme binding motif indicating that both C—O bond formations must be catalyzed by 
the same active site. This is conceivable as both of the oxidized carbons are located in 
such a close proximity that it would only require a slight change in the orientation of 
the bound substrate to facilitate catalysis. In the first stage of catalysis the methylene 
(C-7) adjacent to the pyrone ring is attacked setting the stereochemistry of the 
resulting heterocycle. This is followed by oxidation at C-9a resulting in furan ring 
closure. AurH is the first example of a cytochrome P450 enzyme catalyzing a two-
step cyclization.4 
1.2.1.3 MycG 
MycG is a P450 monooxygenase from biosynthetic pathway of the 16-
membered ring macrolide antibiotic mycinamicin II. Characterization of MycG 
determined that this enzyme catalyzes both the terminal hydroxylation and 
epoxidation events that lead to the final natural product (figure 3B).5,6 MycG’s first 
catalytic task is a hydroxylation at C-14 of the macrolide converting the substrate 
Figure 3. (A) AurH catalyzed reactions. (B) MycG catalyzed reactions. 
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mycinamicin IV to mycinamicin II. Next, MycG performs an epoxidation converting 
the double bond between C-12 and C-13 into an epoxide. The enzyme itself has the 
typical P450 scaffold that is known to accommodate substrates of broad structural 
variety. Based on crystallographic and paramagnetic NMR relaxation data it was 
found that a sequential translocation of the substrate molecule from recognition site to 
the heme catalytic site is most likely responsible for MycG’s ability to perform both 
of its enzymatic functions.7 
 
1.2.1.4 LndM2 
LndM2 is a bifunctional post-PKS oxygenase-reductase from the landomycin 
E biosynthetic pathway. Through a combination of inactivation and feeding 
experiments it was determined that LndM2 is responsible for both the conversion of 
tetrangomycin to rabelomycin and rabelomycin to 11-deoxylandomycinone (figure 
4A). First LndM2 attaches an oxygen atom as a hydroxyl group at the C-6 position of 
the tetracyclic polyketide core producing rabelomycin from tetrangomycin.  This is 
immediately followed by a reduction event creating the pathway intermediate 11-
deoxylandomycinone that can then continue through the biosynthetic pathway to 
A 
B 
C 
Figure 4. (A) LndM2 catalyzed reactions. (B) LanV catalyzed reactions. (C) 
DoxA catalyzed reactions.  
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landomycin E. These two steps of biosynthesis were found to be crucial for the 
dearomatization of the B-ring of the aglycone, an essential feature for recognition by 
the first glycosyltansferase in landomycin E biosynthetic pathway.8  
1.2.1.5 LanV 
LanV is a bifunctional aromatase and ketoreductase from the early portion of 
the landomycin A biosynthetic pathway. Utilizing gene inactivation experiments it 
was found that LanV is first responsible for a 6-ketoreduction followed by a 5,6-
dehydration that leads to the aromatization of the A ring of the aglycone core (figure 
4B). Without this aromatization of the A ring the landomycin A intermediate is not 
recognized by the first glycosyltansferase (LanGT2) and is therefore extremely 
important to this polyketides biosynthesis.9 
1.2.1.6 DoxA 
DoxA is a P450 monooxygenase from the doxorubicin biosynthetic pathway 
and pushes the limits of bifuntionality to its extreme catalyzing three steps in the 
polyketides biosynthetic pathway.10,11 DoxA is responsible for the final three steps of 
doxorubicin’s biosynthesis in which the enzyme is responsible for three consecutive 
oxidative transformations utilizing NADPH and O2 (figure 4C). DoxA first catalyzes 
a hydroxylation at C-13 yielding 13-dihydrodaunorubicin from 13-
deoxydaunorubicin. Next the enzyme catalyzes a second hydroxylation at either C-13 
or C-14 that ultimately results in a spontaneous dehydration and rearrangement to a 
ketone moiety at C-14 producing daunorubicin. DoxA then hydroxylates daunorubicin 
a final time at C-14 yielding the final product doxorubicin.10 
	   	  	  	  	  	  
	  
8	  
 
 
1.2.1.7 EncM 
	   	   EncM is an FAD-dependent ‘favorskiiase’ flavoprotein from the enterocin 
antibiotic biosynthetic pathway responsible for the atypical polyketide aromatization 
of its poly(β-carbonyl) chain into a unique tricyclic caged core. EncM accomplishes 
this task through a rare oxidative Favorskii-type rearrangement.12,13 In vivo 
characterization of the encM gene via mutagenesis and heterologous biosynthesis 
proved this enzyme to be solely responsible for oxidative C—C rearrangement, two 
aldol condensations, and two heterocycle forming reactions creating a total of five 
chiral centers and four rings in the final enterocin chemical structure (figure 5A).13 
EncM was found to exist as a homodimer each with distinct domains for substrate and 
FAD binding (figure 5B). The FAD binding domain sequesters the flavin at the 
interface between the two domains positioning the reactive isoalloxazine moiety in 
optimal proximity for interaction with the polyketide substrate. Additionally, this 
FAD moiety is bound to EncM by a covalent bond between residue His-78 and the C-
EncMO O OOH OH OH O O
S
EncC
1 3 4 5 7 9 11 13 15
(R)-C7,O4-Dihydrooctaketide
OH
S
O
O
O
O
O
EncC
OH
7
4
H2OO2
O
S
O
O
O
O
O
EncC
OH
7
4 O
OO
O
O
O O
S
OH OH
H
Enc
C
3
2
5 10HO O O
[-EncC]
O
O
O
HO
OH
HO O
OH
OH
Demethyl-5-deoxyenterocin
Favorskii-type
 rearrangement
Figure 5. (A) EncM C-4 dual oxidation and rare Favorskii-type rearrangement 
from the enterocin biosynthetic pathway.  (B) Structure of EncM homodimer 
with chain A shown in a lighter shade than chain B. The FAD binding domain is 
shown in pink, the substrate binding domain in shown in blue, and the FAD 
cofactor is shown in yellow.  
A 
B 
9	  
8 methyl group of the flavin’s isoalloxazine ring system. Utilizing co-crystallization 
with the natural substrate, a substrate analogue, and site directed mutagenesis studies 
it was revealed that the terminal benzene group sits at the hydrophobic end of a long 
tunnel and forms aromatic–aromatic interactions with Tyr-150 and Trp-152 and van 
der Waals interactions with Leu-357. Additionally, it was found likely that the C-1 
enol engages in hydrogen bonding with O-4 of the flavin and that the C-3 ketone 
twists away from the flavin and may accept a hydrogen bond from the side chain of 
Glu-355 and possibly from Tyr-249. The orthogonal sections of the bent EncM 
ligand-binding pocket separate the C-1—C-6 triketide head from the C-8—C-15 
pantothenate-linked tetraketide tail to uncouple the reactivity of the entire C-1—C-16 
poly(β-carbonyl) chain preventing kinetically favourable but unwanted cyclization–
aromatization reactions and forcing the less favourable Favorskii-type rearrangement 
(figure 5A).   Based on structural data, EncM’s proposed mechanism is as follows: 
EncM first preforms two iterative oxidations at C-4 of substrate (R)-C7,O4-
dyhydroctaketide effectively converting a 1,3-diketone to a 1,2,3-triketone and setting 
up C4 for electrophilic cyclization. This cyclization then triggers the rare Favorskii-
like rearrangement. Finally, EncM catalyzes two aldol condensations between C-2 
and C-9 and between C-10 and C-5, along with heterocycle formation (order 
unknown) to release the final product demethyl-5-deoxyenterocin.14  
1.2.1.8 FkbD 
FkbD is a cytochrome P450 hydroxylase from the terminal steps of the FK506 
macrocyclic polyketide biosynthetic pathway. Although, the exact sequence of events 
in this pathway remains elusive it is know that this enzyme functions twice iteratively 
either before or after 31-O-methylation catalyzed by FkbM (figure 6). It has also been 
suggested that this conversion can happen simultaneous in either order making FkbD 
quite promiscuous in terms of substrate flexibility. FkbD catalyzes consecutive 
hydroxylation and further oxidation to a ketone at the C-9 position of the parent 
compound 9-deoxy-31-O-demethyl-FK506. In conjunction with FkbM the final 
product of FK506 is then produced (figure 6).  
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Figure 6. Proposed FkbD catalytic events from the FK506 biosynthetic pathway  
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1.2.2 Non-iteratively Functioning Post-PKS Bifunctional Tailoring Enzymes 
Non-iteratively functioning post-PKS bifunctional tailoring enzymes can be 
defined as post-PKS tailoring enzymes that function multiple times at different non-
consecutive points within the same biosynthetic pathway. 
1.2.2.1 LanGT1 
LanGT1 is a glycosyltansferase from the landomycin biosynthetic pathway. 
More specifically, LanGT1 is a D-olivosyltransferase responsible for linking a second 
D-olivose to the 4-OH group of another D-olivose.17 LanGT1’s first function in 
landomycin biosynthesis is to add the second sugar to the growing saccharide side 
chain. It then functions again after several other glycosylations catalyzed by different 
glycosyltransferases to add the fifth sugar in side chain (figure 7B).  Landomycin A 
has a hexasaccharide side chain that is important to its biological activity and any 
alterations in this side chain noticeably change the compound’s action, thus the 
function of LanGT1 is crucial to the compounds biosynthesis. It is not usual to see 
glycosyltransferases act multiple times non-consecutively suggesting that this 
glycosyltansferase may have relaxed substrate specificity and could be of use in the 
combinatorial biosynthesis of new biologically active compounds.18 
Figure 7. Landomycin A with glycosylation events catalyzed by LanGT1 (pink) 
and LanGT4 (green) highlighted.    
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1.2.2.2 LanGT4 
LanGT4, like the previously discussed LanGT1, is a glycosyltansferase from 
the landomycin biosynthetic pathway. LanGT4 differs in that it is a L-
rhodinosyltransferase and is responsible for attaching L-rhodinose to the 3-OH group 
of a D-olivose.17 First, LanGT4 attaches the third L-rhodinose sugar moiety to the 
growing saccharide side chain. Then, after two more glycosylations by LanGT3 and 
LanGT1 respectively, LanGT4 adds the final L-rhodinose to the side chain yielding 
the final product landomycin A (figure 7B). This enzyme is of interest for the same 
reasons previously mentioned for LanGT1.18 
1.2.2.3 MtmGIV 
MtmGIV is a glycosyltansferase from the mithramycin biosynthetic pathway. 
This enzyme’s first role in mithramycin’s biosynthesis is to create the linkage of the 
first sugar moiety, D-olivose, of what will become the trisaccharide side chain to the 
12a-position of premithramycinone creating premithramycin A1 (figure 8A).19,20 
MtmGIV’s second action in the mithramycin biosynthetic pathway is to attach the 
third sugar, D-mycarose, to complete the compounds trisaccharide side chain (figure 
8A). MtmGIV also was found to be capable of accepting TDP-D-quinovose, TDP-D-
Figure 8. (A) MtmGIV catalyzed glycosylation from the mithramycin 
biosynthetic pathway.  (B) Dual reactions catalyzed by MtmC from the 
mithramycin biosynthetic pathway. 
A B 
O
O H3C
HO
OTDP
SAM
NADPH
O
O H3C
H3C
OTDP
OHO
H3C
HO
OTDP
OH
TDP-4-keto-D-olivose
TDP-4-keto-D-mycarose
TDP-D-olivose
MtmC
O
O O O
O
OH OH O
H3C
O
O
OO
O
HO
HO
CH3OH
HO
H3C
OH
HO
HO
O
CH3
OH
OH
OCH3
H
H3C H3C
H3CH3C
Mithramycin
MtmGIV
13	  
digitoxose, and TDP-4-keto-D-digitoxose as substrates for its first functionality 
creating the new mithramycins D-quinovosylpremithramycinone, D-
digitoxosylpremithramycinone, and 4-keto-D-digitoxosylpremithramycinone 
respectively.  Interestingly, this range of substrate promiscuity was not found to be 
the same for MtmGIV’s second functionality. It is important to note that MtmGIV is 
the first glycosyltansferase found to have two unique donor and acceptor substrates. 
This distinctive feature makes MtmGIV an enticing target for future enzyme 
engineering towards the creation of new mithramycin analogues.19  
1.2.2.4 MtmC 
MtmC is a reductase/methyltransferase from the deoxysugar portion of the 
mithramycin biosynthetic pathway. Remarkably, this enzyme can utilize one substrate 
to catalyze reactions creating two different TDP activated sugar moieties. During 
MtmC’s reductase functionality the enzyme reduces its substrate TDP-4-keto-D-
olivose to TDP-D-olivose by reducing the 4-keto group to a hydroxyl group with the 
aid of the cofactor NADPH. During MtmC’s methyltransferase functionality the 
enzyme methylates the same substrate, TDP-4-keto-D-olivose, at the C-3 position 
using SAM as a methyl donor to yield TDP-4-keto-D-mycarose. How this enzyme 
dictates which catalytic event a substrate will be subjected to somehow involves its 
interaction with MtmGIV. This interaction will be discussed in more detail in section 
1.3.2.2 of this review.19  
1.2.2.5 Anm21 
Anm21 is a dual functioning carbamoyltransferases from extended 
ansamitocin biosynthesis responsible for the creation of 4”-carbamoyl 
ansamitocinoside P-3. Through in vivo and in vitro validation this enzyme was found 
to be not only responsible for a carbamoylation at the C-7 position of the polyketide 
macrolactam backbone, but also was found to be responsible for the carbamoylation 
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of the C-4 hydroxyl group of the N-glycosyl moiety in ansamitosinoside P-3 (figure 
9A).  Interestingly, Asm21 was found to contain about 100 additional amino acids at 
it C-terminus when compared to other carbamoyltransferases from various antibiotic 
biosynthetic pathways. Additionally, the enzyme was able to accept a variety of 
ansamitocinoside structures as substrates demonstrating very high substrate 
flexibility. Due to this this broad substrate range Asm21 could theoretically be used to 
develop a variety of ansamitocin drug candidates.21 
1.2.2.6 TcmN 
TcmN is a dual functioning enzyme from the early post-PKS modification 
portion of the tetracenomycin biosynthetic pathway. TcmN’s first function in 
tetracnomycin’s biosynthesis is to dictate the regiospecificity of the first ring 
cyclization. In this role TcmN assures that an intermolecular aldol condensation 
occurs between the C-9 carbonyl and the C-14 methylene. If TcmN is not present this 
reaction can occur one of two ways. The first of which is between the C-9 carbonyl 
and the C-14 methylene as previously mentioned and the second is between the 
Figure 9. (A) Carbamoylations catalyzed by Asm21 from extended ansamitocin 
biosynthesis. Numbering denotes the order in which the carbamoylations occur.   
(B) TcmN functions in the early post-PKS steps of the tetracenomycin 
biosynthetic pathway. (C) Enzymatic activity of OvmII from the oviedomycin 
biosynthetic pathway. 
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between the C-7 carbonyl and the C-12 methylene group (figure 9B). This  implicates 
that TcmN functions to determine regiospecificity but does not preform the aldol 
condensation itself. TcmN’s second functionality is that of an aromatase aromatizing 
the second ring of the polyketide intermediate shown in figure 9B.22 Additionally, the 
C-terminal portion of TcmN has been implicated in the post-PKS O-methylation of a 
tetracenomycin C precursor although this function has never been unequivocally 
verified.1 
1.2.2.7 OvmOII 
OvmOII is a dehydratase/oxygenase form the oviedomycin biosynthetic 
pathway (figure 9C). This enzymes activity has thus far been deduced via in vivo 
methods. OvmOII’s first catalytic function is a 2,3-dehydration event that aromatizes 
the A ring of the polyketide creating 3-dehydrorabelomycin from rabelomycin. Next, 
OvmOIII preforms a 2-hydroxylation yielding 2-hydroxy-dehydrorabelomycin in 
preparation for OvmII’s second functionality. OvmII then converts 2-hydroxy-
dehydrorabelomycin to the final product oviedomycin via a 4-oxidation.23 
1.3 Co-dependent Post-PKS Tailoring Enzymes 
Until recently, it was commonly accepted the post-PKS tailoring enzymes 
were independently functioning. Recently, this has increasingly proven not to be the 
case. Co-dependent enzymes rely on their partners in one or more ways such as by 
providing structural support, providing cofactors, and through sequestration of highly 
reactive intermediates from solvent. For the purpose of this discussion, these co-
dependent enzymes can be grouped into two major categories: consecutively 
functioning and non-consecutively functioning. 
1.3.1 Consecutively Functioning Co-dependent Post-PKS Tailoring Enzymes 
Consecutively functioning co-dependent post-PKS enzymes can be defined as 
post-PKS enzymes that require one or more enzyme partners that each function 
consecutively in a polyketide natural product’s biosynthetic pathway.  
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1.3.1.1 LanZ4-LanZ5 
LanZ4 and LanZ5 are a co-dependent enzyme pair from the landomycin 
biosynthetic pathway. LanZ4 is a FMN-NADPH reductase while LanZ5 is an 
oxygenase. LanZ4 supports LanZ5 by providing the reduced FMNH2 cofactor 
required for catalysis.  The major collaborative activity of this enzyme pair is the 
conversion of landomycin H to landomycin I via a hydroxylation at C-11. 
Landomycin I can then be subjected to various glycosylation events to create the 
major products landomycins A, B, D, and E (figure 10A). In order for LanZ4-LanZ5 
to function appropriately, LanGT2 must glycosylate the aglycone prior to their 
activity. If glycosylation does not occur LanZ4-LanZ5 creates the minor products of 
anhydrolandomycinone and tetrangulol from 11-deoxylandomycinone that can go on 
to be glycosylated to create the minor products landomycin M, O, P, R, T, U, and W 
(Figure 10B).24  
 
1.3.1.2 TamI-TamL 
TamI and TamL are an oxidative co-dependent enzyme pair from the 
tirandamycin biosynthetic pathway. TamI is a P450 enzyme that catalyzes at least two 
hydroxylations and an epoxidation at three distinct sites during the conversion of 
tirandamycin C (TirC) to tirandamycin B (TirB) (figure 11A). The TamI/TamL 
Figure 10. (A) Major pathway of LanZ4-LanZ5 from landomycin biosynthesis.  
(B) Minor pathways of LanZ4-LanZ5 from landomycin biosynthesis. 
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catalyzed cascade occurs in a precisely defined order without any detectable 
promiscuity. The cascade starts when TirC is oxidized at position C-10 to 
tirandamycin E (TirE) by TamI. TamL then oxidizes this hydroxyl group at C-10 to a 
ketone to produce tirandamycin D (TirD). Next, TamI epoxidates TirD at positions C-
11/C-12 yielding tirandamycin A (TirA). To complete the cascade, TirI hydroxylates 
position C-18 to produce TirB. This unique mechanism was further investigated 
through the crystallization and X-ray structural determination of TamL alone (PDB 
ID 2Y08) and the TamL-tirandomycin complex (PDB IDs 2Y3R, 2Y4G, and 2Y3S). 
Together, these structures reveal that TamL functions as a homodimer in which the 
tirandomycins are bound in the active site with the bicyclic ketal group facing the 
FAD cofactor and the tetramic acid moiety extended toward the mouth of the 
substrate binding cleft (figure 11C). Additionally, the FAD cofactor was shown to be 
bicovalently bound by His-52 and Cys-122. Based on residue positioning in the active 
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site, it is hypothesized that TamL oxidation is likely to proceed via proton extraction 
from the C-10 hydroxyl group of the substrate TirE by Tyr-447 and simultaneous 
hydride transfer from the C-10 carbon to the N-5 nitrogen of FAD. Tyr-136 is also 
thought to precipitate in this proton transfer network by initiating the proton 
abstraction from Tyr-447 (figure 11B).25 It is known that the oxidative modifications 
of the tirandamycin biosynthetic pathway are key to antibiotic potency,26 which may 
have created evolutionary pressure toward the development of the TamI/TamL 
system. 
1.3.1.3 PgaE-PgaM  
PgaE and PgaM are a co-dependent sequentially functioning pair of enzymes 
from the early steps of angucycline biosynthesis. PgaE functions as a hydroxylase 
while PgaM functions as a reductase and as an oxygenase in this pathway.  PgaE first 
catalyzes a hydroxylation of UMW6 at position C-12 followed by quinone formation. 
Next, PgaE passes the substrate to PgaM where the reductase domain preforms a 2,3-
dehydration reaction. PgaM’s oxygenase domain then preforms a C-12b 
hydroxylation utilizing water as an oxygen donor. This cascade is completed by a 
stereospecific ketoreduction at position C-6 also catalyzed by PgaM. Mechanistically, 
the oxidative reactions of PgaM are thought to proceed through a highly polarized 
quinone methide intermediate (o-QM) (figure 12A).27  
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1.3.1.4 PdmH-PdmK-PdmL 
PdmH, PdmK, and PdmL are a synergistic trio of co-dependent enzymes from 
the pradimicin A biosynthetic pathway. PdmH is a monooxygenase while PdmK and 
PdmL are cyclases. It was originally predicted that each of these enzymes could work 
independently, but following in vivo studies it became clear that upon removal of any 
one of these genes from the cluster the pradimicin aglycone was no longer produced. 
These surprising results lead to the conclusion that PdmH, PdmK, and PdmL form a 
complex that oxidizes the cyclized-B ring and cyclizes portions of the polyketide 
substrate as shown in figure 12B. PdmH is theorized to be positioned in close 
proximity to the B-ring to hydroxylate C-8, while PdmK and PdmL are likely 
positioned near the two ends of the polyketide chain to preform the aldol 
condensations between C-5 and C-17 and between C-4 and C-21 yielding the product 
A 
B 
Figure 12. (A) PgaE and PgaM catalyzed reactions from gaurdimycin C 
biosynthesis. (B) Reactions catalyzed by the PdmH-PdmK-PdmL trio of enzymes 
from pradimicin A biosynthesis. 
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shown in figure 12B.28 
1.3.1.5 MtmOIV-MtmW 
MtmOIV and MtmW are a pair of co-dependent enzymes from the end of the 
mithramycin biosynthetic pathway. MtmOIV is a Baeyer-Villeger monooxygenase 
responsible for creating the lactone intermediate and subsequent ring cleavage to 
mithramycin DK from premithramycin B shown in figure 13A.29,30 MtmW is a 
ketoreductase that reduces the 4’ ketone of mithramycin DK’s pentyl side chain yielding 
the final product of mithramycin.31 Based on in vitro and in vivo studies the intermediate 
mithramycin DK rapidly degrades to mithramycin SK, SDK, and SA in solution (figure 
13A). Because of this rapid degradation it can only be concluded that MtmOIV and 
MtmW must be in interacting closely to enable the passing of mithramycin DK to 
MtmW.  MtmOIV has been studied much more extensively then MtmW because despite 
multiple attempts MtmW has yet to be produced heterologously in soluble form.  
MtmOIV’s structure has been solved with and without substrate (premithramycin B) as 
shown in figure 13B.29,32,33 This structure is one of only a few Baeyer-Villeger 
monooxygenases and is the most complex in terms of the enzyme and substrate structures 
know to date.32 MtmOIV functions as a homodimer and is FAD and NADPH dependent. 
Prior to this enzymes activity, none of the tetracyclic premithramycin intermediates are 
biologically active making MtmOIV key to this natural product’s biosynthesis.29,30,34  
21	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1.3.2 Non-consecutively Functioning Co-dependent Post-PKS Tailoring Enzymes  
Non-consecutively functioning co-dependent post-PKS enzymes can be 
defined as post-PKS enzymes that require one or more enzyme partners that each 
function at different non-consecutive points in a polyketide natural product’s 
biosynthetic pathway. 
 
1.3.2.1 GilM-GilR 
  GilM and GilR are a non-consecutively functioning pair of co-dependent 
enzymes from the gilvocarin biosynthetic pathway. GilM is an FADH2 dependent 
reductive O-methyltransferase responsible for quinone reduction, hemiacetal 
Figure 14. (A) GilM and GilR co-dependent reactions from the gilvocarcin 
biosynthetic pathway emphasizing the shared FAD cofactor.  (B) GilR 
homodimer crystal structure with one dimer shown in red and the other in blue. 
Pregilvocarcin V substrate is shown in green and the FAD cofactor is shown in 
yellow. (C) Proposed GilR catalytic mechanism.  
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formation, and O-methylation. Structurally, it is known the GilM is a homodimer in 
solution and co-purifies with the SAM cofactor. Its interaction with GilR was proven 
via in vitro experimentation during which GilM produced an increased amount of 
defucogilvocarcin when GilR was present. GilM functions first during biosynthesis 
prior to glycosylation and catalyzes quinone reduction, hemiacetal formation, and O-
methylation of the substrate shown in the reaction in figure 14A with the aid of SAM 
to yield defuco-pregilvocarcin. Defuco-pregilvocarcin is then glycosylated by GilGT 
before being passed to GilR as pregilvocarcin.35 GilR is an FAD dependent 
oxidoreductase that catalyzes the terminal step of gilvocarcin V biosynthesis and 
establishes the lactone core of the polyketide-derived gilvocarcin chromophore 
(figure 14A).36,37 GilR catalyzes the final step in the pathway by the mechanism 
shown in figure 13C during which Tyr-448 aided by Tyr-139 abstracts the proton of 
the 6-OH group of pregilvocarcin, with concomitant hydride transfer of 6-H to N-5 of 
the FAD cofactor. The latter process is facilitated by Tyr-445, which protonates the 2-
C=O group of FAD, thereby enhancing the electrophilicity of its N-5 position. 
Structurally, GilR functions as a homodimer as it is found as a homodimer in solution 
and crystalized. The structure of GilR also reveals the FAD cofactor is bicovalently 
bound by His-65 and Cys-125 (figure 14B).37 The combined knowledge of GilR’s 
FAD cofactor being bicovalently bound and GilM needing GilR to function properly 
lead to the hypothesis that this pair share the FAD cofactor that is bound to GilR 
effectively creating a shared FAD regeneration system.35,37  
1.3.2.2 MtmC-MtmGIV 
MtmC and MtmGIV are a non-consecutively functioning pair of co-dependent 
enzymes from the mithramycin biosynthetic pathway. These enzymes were both 
discussed previously as non-iteratively bifunctional enzymes in sections 1.2.2.5 and 
1.2.2.4 respectively. As stated previously, MtmC is a reductase/methyltransferase 
from the deoxysugar portion of the mithramycin biosynthetic pathway (figure 8B) and 
MtmGIV is a glycosyltansferase responsible for the transfer of the first and third 
sugar moieties to the trisaccharide side chain (figure 8A). In addition to their 
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remarkable bifunctionality MtmC and MtmGIV have been shown to work 
cooperatively via in vitro enzyme reactions. During in vitro characterization of MtmC 
the methylated product of MtmC, TDP-4-keto-D-mycarose, was unable to be observed 
due to instability even though the SAM cofactor utilized by this reaction was being 
depleted. This indicated that the product was being formed but was unstable in 
solution. To overcome these instability issues MtmC’s reactions were coupled with 
MtmGIV’s reactions producing the full trisaccharide side chain intermediated 
premithramycin A3 from the substrate premithramycin A2’ necessitating that these 
reactions are linked and that the enzymes are co-dependent.19  
 
1.4 Conclusions 
  If post-PKS tailoring enzyme bifunctionality and co-dependence were 
considered a common possibility many currently perplexing experimental outcomes 
could easily be explained or more thoroughly investigated for understanding. 
Bifunctional post-PKS tailoring enzymes appear to be more common then co-
dependent enzymes but that may be due to the difficulty of detecting and confirming 
enzyme co-dependence. With regard to co-dependent enzymes there is a need to study 
the mechanism of their protein-protein interactions, as there are currently no in depth 
studies of these interfaces. For both bifunctional and co-dependent post-PKS enzymes 
there is a need for more structural information. Of the few structures that have been 
solved and studied very unique and interesting features have been found such as 
covalently and bicovalently bound FAD cofactors and complex binding sites. Post-
PKS enzymes offer a real opportunity to create new medically relevant compounds 
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via combinatorial biosynthesis and enzyme engineering. If this opportunity is to be 
fully exploited more information about these complex systems is needed making 
bifunctional and co-dependent tailoring enzymes the new frontier of combinatorial 
biosynthesis.  
1.5 Specific Aims 
1.5.1 Specific aim 1 was to investigate the structure of MtmOIV and the role of 
active site residues in its catalytic mechanism.  
The drastically improved protein structure of MtmOIV along with the high-
resolution structure of MtmOIV in complex with its natural substrate premithramycin B 
reveals previously undetected key residues that are important for substrate recognition 
and catalysis. Kinetic analyses of selected mutants allowed probing of the substrate 
binding pocket of MtmOIV and confirmation of the putative NADPH binding site. This is 
the first substrate-bound structure of MtmOIV and the most complex BVMO-substrate 
complex structure known to date providing new insights into substrate recognition and 
catalysis. This investigation paves the way for the future design of a tailored enzyme for 
the chemo-enzymatic preparation of novel mithramycin analogues.	    
1.5.2 Specific aim 2 was to integrate the function of GilM and its protein-protein 
interactions with GilR that lead to their synergistic activity and sharing of GilR’s 
bicovalently bound FAD moiety.  
GilM was determined to be a key enzyme of the gilvocarcin pathway exhibiting 
dual functionality as a reductase and O-methyltransferase responsible for the reduction of 
a quinone intermediate to a hydroquinone, associated stabilizing O-methylation, and 
hemiacetal formation. Additionally, GilM was found to mediate its reductive catalysis 
through the assistance of GilR. GilR provides its bicovalently bound FADH2 cofactor for 
the GilM reaction. In turn GilM regenerates FAD for GilR’s next catalytic cycle 
establishing a unique co-dependent relationship. This unusual synergy eventually 
completes the biosynthesis of the polyketide-derived defuco-gilvocarcin chromophore. 
Additionally, the nessessary enzyme-enzyme interaction between GilM and GilR was 
26	  
probed revealing the absence of a long-lived interface between the two and alluding to a 
transient relationship during catalysis.  
Copyright © Theresa Downey 2014 
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2 Molecular Insight into Substrate Recognition and Catalysis of Baeyer-Villiger 
Monooxygenase MtmOIV, the Key Frame-modifying Enzyme in the Biosynthesis of 
Anticancer Agent Mithramycin. 
2.1 Abstract 
Baeyer-Villiger monooxygenases (BVMOs) have been shown to play key roles 
for the biosynthesis of important natural products. MtmOIV, a homodimeric FAD- and 
NADPH-dependent BVMO, catalyzes the key frame-modifying steps of the mithramycin 
biosynthetic pathway, including an oxidative C-C bond cleavage, by converting its 
natural substrate premithramycin B into mithramycin DK, the immediate precursor of 
mithramycin. The drastically improved protein structure of MtmOIV along with the high-
resolution structure of MtmOIV in complex with its natural substrate premithramycin B 
are reported here, revealing previously undetected key residues that are important for 
substrate recognition and catalysis. Kinetic analyses of selected mutants allowed us to 
probe the substrate binding  pocket of MtmOIV and also to discover the putative NADPH 
binding site. This is the first substrate-bound structure of MtmOIV providing new 
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insights into substrate recognition and catalysis, which paves the way for the future 
design of a tailored enzyme for the chemo-enzymatic preparation of novel mithramycin 
analogues.	  	  
2.2 Introduction  
Baeyer–Villiger monooxygenases (BVMOs), an important subclass of 
flavoprotein monooxygenases, not only have proven to be potent biocatalysts for 
synthetic organic chemistry applications38 but also have been found to hold critical roles 
in the biosynthesis of many natural products.39 Additionally, BVMOs are known to be 
responsible for pro-drug activation40 as well as biodegradation reactions.41–43 
MtmOIV is a homodimeric BVMO from the mithramycin biosynthetic pathway 
that catalyzes the key frame-modifying step responsible for producing bioactivity. This 
FAD- and NADPH-dependent enzyme reacts with its natural substrate premithramycin B 
to form mithramycin DK, the substrate of the final enzymatic step of the mithramycin 
biosynthetic pathway.29,44 Mithramycin (MTM, also known as aureolic acid, mithracin, 
LA-7017, PA-144, and plicamycin) is an aureolic acid-type polyketide anticancer 
antibiotic produced by the soil bacterium Streptomyces argillaceus (ATCC 12956) and 
various other species of streptomycetes. The small distinct group of aureolic acid-type 
anticancer antibiotics includes MTM, chromomycin, olivomycin, UCH9, and 
durhamycin, which all contain the same polyketide-derived tricyclic aromatic core with a 
highly functionalized pentyl side chain attached at C-3 but vary with respect to their 
saccharide patterns and side chains in the 7-position.45–47 
The structure of MTM consists of a tricyclic aglycone core, a highly 
functionalized pentyl side chain at the 3-position, and five deoxysugars linked as a 
trisaccharide at the 2-position and a disaccharide at the 6-position, respectively. MTM 
biosynthesis proceeds through the polyketide-derived tetracyclic premithramycinone, to 
which the five sugar moieties and one C-methyl group are added leading to 
premithramycin B.19,45–49 Then, MtmOIV oxidatively cleaves the fourth ring via a 
Baeyer–Villiger reaction, generating MTM’s characteristic tricyclic aglycone core and 
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the highly functionalized pentyl side chain at position 3. The Baeyer–Villiger reaction 
precedes lactone opening, decarboxylation, and the final step of MTM biosynthesis, the 
reduction of the 4′-keto group catalyzed by ketoreductase MtmW (Figure 16).31 
MTM exhibits anticancer activity by inhibiting replication and transcription by 
cross-linking of DNA strands predominantly in GC-rich regions used by Sp promoters.50–
52 MTM has been used clinically to treat certain cancers, such as testicular carcinoma,53,54 
and bone diseases, such as Paget’s disease,55–58 and particularly to address cancer-related 
hypercalcemia.59–62 Recent discoveries include MTM’s potential (i) as therapeutic to treat 
Huntington’s disease,63–65 (ii) as a lead drug out of a screen of 50,000 compounds 
affecting Ewing sarcoma promotion factors that previously were believed to be 
“undruggable”,66 and (iii) as a repressor of ABCG2-related stem cell signaling in lung 
and esophageal cancers.67 Yet, the clinical use of MTM is still hindered because of its 
hardly manageable toxicity, which could potentially be reduced through the generation of 
new, less toxic analogues. In this context, the function of the Baeyer–Villiger 
monooxygenase (BMVO) MtmOIV needs to be fully understood to pave the way for 
further chemo-enzymatic and/or combinatorial biosynthetic approaches toward new 
MTM analogues.  
Besides our low resolution structure of MtmOIV44 only a few crystal structures of 
Baeyer–Villiger reaction-performing enzymes are available to date,38 including 
phenylacetone monooxygenase from the thermophilic bacterium Thermobifida fusca,68  
the oxygenating component of 3,6-diketocamphane monooxygenase,69–71 a dimeric 
BVMO catalyzing the lactonization of 2-oxo-Δ(3)-4,5,5-trimethylcyclopentenylacetyl-
CoA, a key intermediate in the metabolism of camphor by Pseudomonas putida,42 and 
cyclohexanone monooxygenase (CHMO) from Rhodococcus sp. HI-31,72 which could 
also be solved in complex with cyclohexanone as well as NADP and FAD.73 Most 
recently, the toxoflavin lyase structure was solved, and the enzyme was found to catalyze 
a degradation reaction via a Baeyer–Villiger oxidation reaction.43 Various BVMOs have 
been described and studied, and most of these appear to be involved in oxidative 
degradation pathways, for which substrates were identified ranging from simple ketones, 
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such as phenylacetone or cyclohexanone and their derivatives, to steroids, such as 
progesterone.38,43,74 In contrast to these mostly monofunctional molecules, the MtmOIV 
substrate premithramycin B (PMB) is a multifunctional and richly decorated molecule 
and thus remains the most complex substrate and one of very few unambiguously proven 
natural BVMO substrates.75 
We have previously reported the native structure of MtmOIV that provided initial 
insights into the intriguing enzymatic BV mechanism.44 However, crystals for this 
structure suffered from a high solvent content that led to many disordered side chains. 
Here, we report the significantly improved crystal structure of native MtmOIV to 2.0 Å 
resolution, as well as the crystal structure of MtmOIV in complex with its natural 
substrate premithramycin B to 1.85 Å resolution, allowing us to identify key residues 
involved in substrate recognition and catalysis. This provides the structural information 
required to re-engineer MtmOIV to have altered substrate specificity for the generation of 
new bioactive analogues of MTM. Our structure of MtmOIV in complex with 
premithramycin B provides insight into substrate recognition and catalysis in MtmOIV 
and other important enzymes from this family. Furthermore, mutagenesis, kinetic assays, 
and docking studies based on a low resolution NADPH-bound co-crystal structure 
allowed us to probe the substrate binding pocket of MtmOIV and to discover the putative 
NADPH binding site, which sits opposite the substrate binding site, yet still in close 
proximity to the FAD cofactor. 
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Figure 17. Mithramycin biosynthetic pathway. (A) The reaction catalyzed by the 
Baeyer–Villiger monooxygenase (BVMO) MtmOIV yields premithramycin B-
lactone, which is further converted to mithramycin DK. Ketoreductase MtmW 
catalyzes the final step of mithramycin biosynthesis. (B) Suggested Baeyer–
Villiger oxidation of premithramycin B (sugar residues not shown) to 
premithramycin B-lactone involving cofactors FADH and NADPH (for FADH 
regeneration).
	   	  	  	  	  	  
	  
32	  
2.3 Results and Discussion 
2.3.1 Overall Structure of MtmOIV 
The crystal structure of native MtmOIV has previously been described.44 
However, the N-terminal fusion tag was not removed, and the structure suffered from 
high solvent content (~70%) that led to a large number of disordered side chains. Here, 
we have removed the N-terminal fusion tag, which led to crystal conditions with overall 
improved quality and significantly improved electron density quality and side chain order 
with ~50% solvent content. The new structure was solved to 2.0 Å resolution in space 
group P2 with one molecule per asymmetric unit. The final structure contains 499 of 533 
total residues (Ala10–Ala509) for MtmOIV and a single noncovalently bound FAD 
cofactor (Figure 17A). Final data collection and refinement statistics are summarized in 
Table 1. Figure 17A shows the three domains of MtmOIV: the FAD binding domain 
Figure 18. Overall structures of MtmOIV and the MtmOIV-premithramycin B 
complex. (A) The improved native MtmOIV crystal structure to 2.0 Å resolution. 
FAD is shown in ball and stick representation. (B) The MtmOIV-premithramycin B 
complex crystal structure showing FAD and premithramycin B in ball and stick 
representation. For both panels, the FAD domain is shown in gold, the middle 
domain in blue, and the C-terminal domain in green. 
33	  
(residues 10–183 and 276–394), the middle domain (residues 184–275), and the C-
terminal domain (residues 395–510). A loop containing residues 218–224, which lies at 
the perimeter of the substrate binding  pocket, was found ordered in the new structure. 
However, the loop containing residues 233–239, which has been suggested to be involved 
in NADPH binding,44 was again found disordered along with a small loop within the C-
terminal domain containing residues 402–403. 
2.3.2 Structure of MtmOIV-PMB Complex 
For the structure of MtmOIV in complex with its substrate premithramycin B 
(PMB), PMB was added to MtmOIV prior to concentrating the protein for crystallization 
trials. Co-crystals were grown in final conditions consisting of 200mM ammonium 
acetate and 30% poly(ethylene glycol) (PEG) 1000, and the structure was solved to 1.85 
Å resolution in space group P2221, with two molecules per asymmetric unit. The final 
structure contains 500 of 533 total residues (Ala10–Asn510) for MtmOIV and a single 
noncovalently bound FAD cofactor per subunit (Figure 17B) with the same domain 
architecture as the native structure (root-mean-square deviation (RMSD) of 0.266 Å for 
2933 aligned atoms). A difference density map revealed the presence of unmodeled 
density along the putative substrate binding  site in which PMB was modeled and refined 
(Figures 17B and 18). Final data collection and refinement statistics are summarized in 
Table 1. 
As shown in Figure 16B, PMB binds MtmOIV within the large binding pocket 
formed between the FAD binding domain and the middle domain, and the sugar chains of 
PMB interact with the inner walls of the middle and the FAD binding domains within the 
pocket. Ignoring any ordered water molecules found in the structure, only a few residues 
from MtmOIV appear to make direct hydrogen bonding interactions with PMB including 
R225 and W205 (Figure 19A), indicating that van der Waals and hydrophobic 
interactions may play a major role in substrate binding and selectivity. When we include 
the ordered water molecules found within the crystal structure, it becomes clear that the 
ordered solvent may also play a major role in substrate binding by forming a hydrogen 
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bonding network that bridges PMB binding within the binding pocket of MtmOIV 
(Figure 19B). A Ligplot analysis of the interactions between PMB and MtmOIV depicts 
best the vast number of interactions involved in substrate binding involving not only 
protein side chains but also many water molecules that are crucial for binding (Figure 
19C). 
 The improved native (substrate-free) MtmOIV crystal structure described above 
allowed us to compare the substrate-free and substrate-bound crystal structures. The 
overall conformation of MtmOIV in the complex structure was the same as in the native 
structure; however, a minimal domain shift was observed within the middle domain 
relative to the FAD binding domain (more open), which likely serves to accommodate the 
bound substrate. While only minimal rearrangements were observed for most of the side 
chains of residues lining the substrate binding pocket, the largest shifts appear in W205 
(1.6 Å along atom CH2) and F89 (0.9 Å along atom Cζ), which sit on opposite sides at the 
entrance to the substrate binding pocket. Aside from these slight shifts, no major 
conformational differences were observed between the substrate-free and substrate-bound 
states of MtmOIV. 
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Table 1. Data Collection and Refinement Summary 
a 
Indicates statistics for last resolution shell shown in parentheses. 
b
 Rsym = Σhkl,j (|Ihkl – Ihkl|)/Σhkl,j Ihkl, where Ihkl is the average intensity for a set 
of j symmetry-related reflections and Ihkl is the value of the intensity for a 
single reflection within a set of symmetry-related reflections. 
c 
R factor = Σhkl (Fo| – |Fc)/Σhkl |Fo| where Fo is the observed structure factor 
amplitude and Fc is the calculated structure factor amplitude. 
d
 Rfree = Σhkl,T (Fo| – |Fc)/Σhkl,T |Fo|, where a test set, T (5% of the data), is 
omitted from the refinement. 
e
 Performed using Procheck. 
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Figure 19. Stereoview showing the electron density for FAD and premithramycin 
B. The middle domain in shown in blue, the FAD domain is in gold, both FAD 
and premithramycin B (PMB) are shown in ball and stick representation, and 
the electron density (SA-omit Fo – Fc map contoured to 2.5 σ) is shown as a green 
transparent isosurface. 
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Figure 20. Premithramycin B binding site in MtmOIV. (A) Shown are the 
interactions (dashed lines) of MtmOIV with premithramycin B (PMB) bound 
along the active site with water molecules removed from structure. Without 
water molecules, there appear to be two primary interactions with W205 and 
R225, with van der Waals and hydrophobic interactions contributing a large 
part to the binding energy. (B) Shown are the interactions of MtmOIV with 
PMB, including the water molcules that were observed in the crystal structure 
(1.85 Å resolution). Once solvation is included, a vast number of interactions 
(dashed lines, distance cutoff of 3.3 Å) are observed that are bridged by ordered 
water molecules, indicating that hydrogen bonding networks play a major role 
in substrate binding. (C) Ligplot of PMB bound to MtmOIV indicating 
important interactions (dashed lines, distance cutoff of 3.3 Å). For clarity, atom 
names for PMB have been removed, and only water molecules (cyan spheres) 
having two or more hydrogen bonding interactions are shown. 
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2.3.3 Mutagenesis and Steady State Kinetics Assays 
Using the structure of MtmOIV in complex with PMB, we were able to identify 
residues important for substrate recognition (P84, F89, R204) and catalysis (H50, D51, 
W205, R225) (Figure 20A). We mutated these residues to alanine and then used a kinetic 
assay to determine the effect each mutation had on substrate binding and catalysis (Figure 
20B–D and Table 2). While the substrate binding of mutants was relatively tolerant to 
most of the mutations, turnover rates for several of the mutants were severely affected. 
Interestingly, none of the substrate recognition site mutants significantly affect substrate 
binding except the double mutant P84A/F89A with a ~50-fold decrease in KM compared 
to the wild-type enzyme, leading to a 3-fold increased catalytic efficiency. The single 
mutants F89A, P84A, and R204A decrease KM only by 3–10-fold; however, their 
catalytic efficiencies are even greater than that of the double mutant due to a less severe 
decrease in kcat. The active site mutant W205A is interesting since its catalytic efficiency 
is drastically decreased (~30-fold), although the substrate binding is comparable to that of 
the wild-type enzyme, likely because of its role as gatekeeper for the entry into the 
binding pocket (see below). Arginine-225 appears crucial; its mutation led to a 
noncatalytic enzyme. Figure 19 illustrates that R225 stabilizes the polyketide core of 
PMB. Interestingly, the D51A mutant, like the previously reported F89A mutant, showed 
a ~2-fold increase in kcat and a drastically increased catalytic efficiency, which proves the 
crucial role of this amino acid for MtmOIV’s catalysis of the BV reaction. It is possible 
that changing the carboxylate residue of aspartate into the simple methyl group of alanine 
may decrease both sterically and electronically disadvantageous interactions between the 
substrate PMB and the peroxyflavin (Table 2, Figures 16 and 19). 
39	  
Figure 21. Probing substrate recognition and catalysis in MtmOIV. On the basis 
of structural analysis, three regions were initially targeted for this study to 
determine their contribution to substrate binding and catalysis (see Table 2). (A) 
Shown is the MtmOIV-premithramycin B (PMB) crystal structure with the 
location of the mutations that were made shown as spheres and color coded by 
their predicted role in catalysis: (i) substrate binding (magenta), (ii) active site 
(orange), and (iii) putative NADPH binding (cyan). The FAD domain is shown in 
gold, the middle domain in blue, the C-terminal domain in green, and both FAD 
and PMB are shown in ball and stick representation. (B) Sample of raw kinetic 
data collected at λ = 340 nm. (C) Michaelis–Menten curve fitting of data for WT 
MtmOIV and mutants. (D) Curve fitting of data for WT MtmOIV and the 
mutants R169A, R173A, R174A, and R277A. 
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Table 2. Summary Table of MtmOIV Mutagenesis and Kinetics Assays 
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2.3.4 Identification of the Putative NADPH Binding Site of MtmOIV	  
We recently grew crystals of MtmOIV in the presence of 5 mM NADPH that 
diffracted to ~3.5 Å (data not shown). We were able to solve the structure and observed 
density for the putative NADPH binding loop (residues 233–239), which had previously 
always been found disordered, as well as for a possible NADPH molecule found at a 
novel binding site along the second identified Rossmann-type fold (residues 163–180 
correspond to a single β-α-β super secondary structural motif commonly found in 
Rossmann folds), which is distinct from either the FAD or the substrate binding sites 
(Figure 22A and B). However, due to the low resolution of the data and partial disorder 
within the ligand, we were not able to model the entire NADPH molecule, and our efforts 
to improve the resolution of the crystals have so far been unsuccessful. Yet, on the basis 
of the location of the density, we were able to identify four residues (R169, R173, R174, 
R277) that seem well positioned to interact with NADPH at this site (Figure 21A and B). 
Mutating these residues to alanine significantly altered the catalysis of MtmOIV, 
although the KM values of the mutants still indicate similar NADPH binding as found for 
the wild-type enzyme. We assume that inactivating single arginine residues leads to a 
distorted NADPH binding that precludes efficient reduction of FAD and therefore 
efficient enzyme turnover. Unexpectedly, PMB binding seems to be enhanced upon 
changing the latter three of these four arginine residues (Table 2),76 possibly because the 
access of substrate PMB is facilitated if NADPH is bound less efficiently to the enzyme. 
All four arginine residues are fully conserved in other FAD- and NADPH-dependent 
monooxygenases, e.g., PgaE and CabE,77 two enzymes with a similar fold as MtmOIV 
(Figure 21C and D). These R to A mutants seem not to affect FAD binding, since they 
keep the same bright yellow color as the wild-type enzyme. 
Using this information along with the recently reported protein structure of 
CHMO in complex with NADP73 and the suggested role of the disordered loop 
containing residues 233–239 for NADPH binding, we performed steered docking studies 
using AutoDock 4 to form an in silico model for the NADPH-bound state of MtmOIV 
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(Figure 22). The putative NADPH binding site is formed by the outer edge of the FAD 
binding domain and the middle domain and is located on the opposite side of the 
substrate binding pocket, but in close proximity to the FAD cofactor. Together, our 
structural and mutagenesis studies have allowed us not only to identify both the exact 
FAD and substrate binding sites but also to identify the putative NADPH binding site. 
Figure 22. Low resolution crystal structure of NADPH bound to MtmOIV. (A) 
The ordered NADPH binding loop of MtmOIV showing 2Fo – Fc electron density 
(gray) contoured at 0.8 σ. Difference density (green) contoured at 2.5 σ for 
NADPH that was observed only in this crystal structure and not within any of the 
previous MtmOIV structures. The space group for the NADPH-bound co-crystal 
structure was P1 with 6 molecules in the asymmetric unit. The resolution was 3.5 
Å, and final R/Rfree values are 0.22/0.26. (B) Rigid body placement of NADPH 
along the difference density within the MtmOIV structure, which was used as a 
starting point for subsequent docking studies. (C) Sequence alignment showing 
the conservation of basic residues at the putative NADPH binding site. (D) 
Structural alignment of MtmOIV (gold), PgaE (light purple), and CabE (green) 
depicting residues proposed to interact with NADPH shown in stick 
representation. 
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Figure 23. NADPH docked into the putative NADPH binding pocket in 
MtmOIV. (A) The MtmOIV structure showing the bound premithramycin B in 
the substrate binding pocket and the lowest energy docked model (−2.8 kcal/mol) 
of NADPH positioned within the putative NADPH binding pocket. (B) Top-down 
view of the MtmOIV structure shown in panel A through the middle domain 
(blue). The binding pockets in panels A and B are shown as transparent surfaces, 
and for clarity, FAD is shown in stick. (C) Close-up view of the putative NADPH 
binding site shown in proximity to FAD and PMB (ball and stick), which was co-
crystallized within the substrate binding pocket. Middle domain loop consisting 
of residues 233–239 has been postulated to participate in binding NADPH (ball 
and stick) and was found disordered in all known structures of MtmOIV except 
our low resolution NADPH co-crystal structure. Those residues that were 
identified from our low resolution crystal structure to interact with NADPH 
(R169, R173, R174, R277) are shown in stick representation. 
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2.4 Conclusions  
Our new refined structure is the first substrate-bound crystal structure of 
MtmOIV. The MtmOIV structure with its bound substrate PMB revealed significant 
differences to the previous computer model, in which PMB was docked into the low 
resolution structure of MtmOIV.44 Most important, two glutamine residues (Q78 and 
Q91) and a proline residue (P84) were recognized as critical to hold the trisaccharide 
chain in place. The trisaccharide chain is essential for the DNA interaction of the 
anticancer drug mithramycin (MTM) with DNA,78,79 and BVMO MtmOIV, which 
catalyzes the second to last step in MTM biosynthesis, seems to be optimized to 
exclusively process PMB, i.e., a molecule already fully glycosylated with the 5 sugars 
found in the final mithramycin (MTM) molecule. The three above-mentioned 
trisaccharide stabilizing residues were not identified in the previous PMB–MtmOIV 
binding site model but are likely critical for our future attempts to further modify MTM’s 
trisaccharide side chain. Preliminary SAR studies showed that modifications of this 
trisaccharide chain can significantly change the biological activity of mithramycins,80,81 
and it was shown that changing the terminal D-mycarose of the trisaccharide chain into D-
digitoxose led to a significant reduction of toxicity.82 A re-engineered MtmOIV will be 
essential for future approaches to bioengineer MTM variants with alternate trisaccharide 
residues. Proline residue (P84) appears to be pivotal to accommodate the trisaccharide 
chain of the substrate PMB. Interestingly, a P84A mutation increased the catalytic 
activity of MtmOIV almost 1.5-fold, but seems less effective than the previously 
generated F89A mutant, which led to a 5-fold activity increase. Combining these 
successful mutations in a P84A/F89A double mutant failed, since the double mutant led 
to only a 3-fold increased catalytic activity. In contrast to the longer trisaccharide chain 
that interacts well inside the PMB binding pocket, the shorter disaccharide chain of PMB 
seems to establish no particular interaction with that pocket (Figure 19) and may serve as 
a mechanical block along with the gatekeeper residues W205 and F89 (see below) to 
allow only a certain degree of penetration of the PMB molecule into its binding pocket. 
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The new MtmOIV protein structures discussed here also revealed that a 
tryptophan (W205), arginine (R204), and phenylalanine (F89) residue that play key roles 
in guarding the entry loop during the substrate binding process. Comparing the substrate-
free and the substrate-bound structures on MtmOIV showed the largest shifts for W205 
(1.6 Å) and F89 (0.9 Å), which sit on opposite sides at the entrance to the substrate 
binding  pocket. To confirm our hypothesis regarding the W205 residue as key 
gatekeeper, we prepared the W205A mutant, which turned out to be the only mutant that 
negatively affects substrate binding, while the previously published F89A and R204A 
mutants had only marginal effects on the substrate binding and slightly increased 
catalytic activity. In contrast, the W205A mutation decreased the catalytic activity about 
30-fold compared to that of the wild-type enzyme (see Table 2), corroborating W205’s 
role as key gatekeeper that needs to stay intact to correctly place the PMB molecule. The 
new structures also revealed that a histidine (H50) and an aspartate (D51) residue seem to 
be important to fine-tune the positioning of the FAD cofactor. Modifying these could 
affect the catalytic activity of the enzyme. Indeed, in the H50A and D51A mutants an 
increased catalytic activity of 1.5- and 3-fold, respectively, was observed. 
On the basis of a low-resolution complex structure of MtmOIV in complex with 
NADPH, we identified four arginine residues (R169, R173, R174, R277) potentially 
important for binding NADPH. These residues are quite distant from the substrate 
binding  site, and mutants were made to confirm the putative NADPH binding site. The 
mutants showed a clearly diminished catalytic activity of 10–50% relative to the wild-
type enzyme in their ability to reduce NADPH, supportive of the hypothesis that these 
residues contribute to the NADPH binding. Future ligand binding studies to completely 
delineate this enzyme’s complex mechanism may shed greater light on the role each 
NADPH binding arginine plays, especially if product inhibition plays a role and becomes 
the rate-limiting step of catalysis. 
In summary, the high resolution structures of MtmOIV revealed new details of 
this important bottleneck enzyme of the MTM biosynthesis pathway, and the subsequent 
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structural mutations pointed out possible strategies for the broadening of its substrate 
specificity and enhancement of its catalytic activity. 
2.5 Methods  
2.5.1 MtmOIV Cloning 
MtmOIV was cloned from genomic DNA using Pfu polymerase. The gene and 
Pet28a(+) vector were individually dually digested with NdeI and EcoRI restriction 
enzymes for 1 hour at 37 °C and purified using 8% agarose gel electrophoresis and 
Qiagen miniprep columns. 1 µl of digested vector and 9 µl digested insert gene were 
combined in a 20 µl ligation reaction with T4 ligase and allowed to incubate overnight at 
room temperature. Each ligation reaction was then transformed into XL1-blue chemically 
competent sells by heat shocking the cells combined with the 20 µl ligation reaction for 
Figure 24. Diagram of MtmOIV protein expression and purification. 
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30 seconds at 42 °C. The cells were allowed to recover for 1 hour in 200 µl LB 
(Lysogeny Broth) at 37 °C and then plated on LB agar plates supplemented with 
50µg/mL kanamycin for resistance selection. Each plate was incubated overnight at 37 
°C and several of the resulting colonies were selected and grown overnight in 5 ml LB 
media supplemented with 50 µg/mL kanamycin. Plasmid was recovered from each of 
these 5 ml overnight cultures using Qiagen miniprep spin columns. 5 µl of each plasmid 
was digested with NdeI and EcoRI for 1 hour at 37 °C and checked for the correct size 
gene insert using 8% agarose gel electrophoresis. Digested plasmid with the correct size 
insert and vector backbone were sent to Genewiz Inc. for DNA sequencing using their 
stock T7 and T7 terminator sequencing primers and high gc content DNA sequencing 
protocol.  
2.5.2 Protein Expression, Purification, and Crystallization 
Figure 25. Diagram of histag cleavage and further purification for X-ray 
crystallography.   
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The cloning and overexpression of MtmOIV was performed basically as 
previously reported44 except that we chose here to remove the N-terminal His6-tag 
leading to better crystallization conditions. Briefly, the mtmOIV coding sequence (1.5 kb) 
was amplified and subcloned into pET28a(+) and expressed with an N-terminal His6 
fusion tag for purification and removed using a Thrombin Cleavage Capture Kit 
(Novagen) prior to crystallization. This construct was then transformed into BL21(DE3) 
cells. A 1 L culture using LB medium supplemented with 0.1 mM kanamycin was grown 
at 37 °C until the OD600 reached 0.5–0.7 and then was induced with 1 mM IPTG 
(isopropyl-β-d-1-thiogalactopyranoside) and allowed to grow at 18 °C for an additional 
12 hours (figure 23).  
For purification, cells were collected by centrifugation, resuspended in lysis 
buffer (50  mM KH2PO4, 300 mM KCl, 10 mM imidazole, pH 8.0), lysed by two passes 
through a French press, and then centrifuged for 45 min at 18000 rpm at 4 °C. The 
supernatant was then passed through a 0.45 µm syringe driven multigrade glass fiber 
filter (Millipore), applied to a Ni-NTA (nitrilotriacetic acid) column using a Profinia 
protein purifier (Bio-Rad), and eluted with 250 mM imidazole. Fractions containing 
MtmOIV were pooled and incubated with biotinylated thrombin (Thrombin Cleavage 
Capture Kit, Novagen) overnight at 4 °C with gentle rocking to remove the His6 fusion 
tag. Thrombin was then removed by treatment with streptavidin-linked agarose beads at 4 
°C with gentle rocking for 30 min. The beads were separated from the cleaved protein by 
centrifugation at 500 × g for 5 min at room temperature using spin filters (Novagen). Free 
cleaved His-tags and uncleaved protein were then separated by passage across a 2 mL 
column of Talon metal affinity resin (Clontech) using lysis buffer. As a final step for 
crystallization, the sample was concentrated to ~200 µL using a Ultracel 30K filter 
(Millipore) and further purified by gel filtration across a Superose 6/300 GL Tricorn high 
performance column (Amersham Biosciences) on a BioLogic DuoFlow HPLC system 
(Bio-Rad) and crystallization buffer (20 mM Tris, pH 7.5, 200 mM NaCl). Fractions were 
collected and concentrated to a final concentration of ~10 mg mL-1. For the MtmOIV–
premithramycin B (PMB) complex structure, PMB (5 mM) was added to the protein 
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solution (~200 µL) 1 h prior to concentration to 10 mg mL-1 for crystallization. Protein 
concentrations were determined by Bradford assay (Sigma) for crystallization and kinetic 
studies. 
For crystallization, broad matrix screening was performed using a TTP LabTech 
Mosquito crystallization robot, and lead conditions were optimized accordingly. Final 
conditions for the native MtmOIV crystals consisted of 100 mM Bis-Tris 6.5 and 28% 
PEG MME (poly(ethylene glycol) monomethyl ether) 2000, while the final conditions for 
the MtmOIV–PMB co-crystals consisted of 200 mM ammonium acetate and 30% PEG 
1000. The best crystals typically grew within 3–5 days at 21 °C, were harvested directly 
from the crystallization drop, and then were plunged into liquid nitrogen for storage until 
data collection. 
2.5.3 Data Collection and Structure Determination 
Lead conditions were initially screened using our in-house X-ray diffractometer 
(Rigaku MicroMax-007 HF microfocus X-ray generator, Raxis IV++ detector). Final data 
sets were collected at the SER-CAT (Southeast Regional Collaborative Access Team) 
beamline at the Advanced Photon Source at Argonne National Laboratory. All data were 
processed using HKL200083 and statistics are summarized in Table 1. Both the native 
MtmOIV and the MtmOIV–PMB complex structures were solved by molecular 
replacement using PHASER84 within CCP4 (Collaborative Computational Project 4).85 
An initial search model was prepared using the previously deposited MtmOIV 
coordinates (PDB code 3FMW). A difference map clearly indicated the locations of the 
FAD molecules within the native MtmOIV structure and the locations of FAD and PMB 
molecules within the MtmOIV–PMB complex structure. 
All model building was performed using COOT (Crystallographic Object-Oriented 
Toolkit),86 and refinement (including automated water picking followed by visual 
inspection) was performed using PHENIX (Python-based Hierarchical Environment for 
Integrated X-ray crystallography)87 and CCP4.85 All figures were prepared using PyMOL 
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(Schrödinger), and final editing was done in Adobe Illustrator. RMSD analysis was 
performed within PyMOL (Schrödinger). 
2.5.4 Modeling the Putative NADPH Binding Site 
We were able to grow crystals of MtmOIV in the presence of NADPH. These 
crystals diffracted to ~3.5 Å, and while we were able to observe extra density indicating 
the presence of NADPH, the density was mostly disordered and incomplete, preventing 
us from modeling the ligand accurately and with confidence. Nevertheless, on the basis 
of the location of the difference density, we were able to identify four residues at this site 
that interacted with the putative NADPH molecule, namely, R169, R173, R174, and 
R277. Mutagenesis of three of these residues proved to have a major impact on catalysis. 
Further, a disordered loop containing residues 233–239 is located along this putative 
NADPH binding site and has been suggested to play a role in binding NADPH. This 
information has allowed us to propose the putative NADPH binding site, which in 
comparison with the substrate binding site sits on the opposite side of the MtmOIV 
Figure 26. NADPH docking box used in the Autodock procedure to model the 
putative NADPH binding site of MtmOIV.    
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structure, yet still in proximity to the FAD cofactor. To model this, we used the 
NADP(+)-bound crystal structure of cyclohexanone monooxygenase (PDB code 3GWF) 
and aligned to MtmOIV along the FAD cofactor, which positioned the NADP(+) 
molecule in the proximity of the putative NADPH binding pocket in a 23Å x 23Å x 23Å 
box with 0.386Å grid spacing and a gridcenter at -23.082, 46.586, -114.336. We then 
added NADPH to our structure at this site and manually optimized the fit to agree with 
the observable density in our low-resolution NADPH-bound structure.	  This was used as 
a starting point for docking studies to optimize the NADPH position within the binding 
pocket. Here, we used AutoDock 4.288–90 and the AutoDockTools89,91–93 to perform the 
docking analysis using the FAD-bound MtmOIV crystal structure as the receptor 
molecule and NADPH as the ligand molecule. Based on the low-resolution co-crystal 
structure with NADPH, the putative NADPH binding loop was added to the receptor 
molecule prior to the analysis. A grid was calculated about the placed ligand, and an 
autodocking procedure was performed using the Local Search algorithm with default 
parameters that preform 300 iterations of lowest energy calculations. The docking 
analysis produced coordinates for the top 50 solutions, which were further sorted on the 
basis of lowest energy, with the top solution, having the lowest energy of −2.8 kcal/mol, 
being used for subsequent analysis. 
2.5.5 Mutagenesis and Kinetics Assays 
MtmOIV mutants were prepared using an Agilent Quikchange site-directed 
mutagenesis kit. Primers used for mutagenesis are shown in Table 4. All kinetic assays 
were repeated in triplicate with no less than two separate purifications of the enzyme. The 
kinetic assays utilized here with respect to the premithramycin-B substrate have been 
previously reported.44 Briefly, we monitored the conversion (100 mM Tris-HCl pH 8.25, 
30 °C, 10 min) of premithramycin B by MtmOIV in a continuous assay measuring the 
oxidation of NADPH at λ = 340 nm (ε 340 = 6220 M–1 cm–1) in the presence of FAD and 
O2 (0.25 mM NADPH/NADH; 0.1 mM FAD added; open cuvette/96 well plate). The 
reactions were initiated by addition of 0.25, 1, 5, or 10 µM wild-type or mutant MtmOIV. 
Kinetic parameters were determined by fitting with Kaleidagraph 4.0 (Synergy). 
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The kinetic assays utilized with respect to the substrate NADPH were monitored via a 
fluorescent assay due to the inability to monitor the reaction at high concentrations of 
NADPH by absorbance because of absorbance values exceeding the detection limits of 
available spectrophotometers. Fluorescence spectroscopy was used to monitor the 
oxidation of NADPH in the presence of FAD and O2 (2 mM Pre-B; 0.1 mM FAD added; 
open 96-well plate). This conversion was continuously monitored at an excitation λ = 355 
nm and an emission λ = 460 nm (100 mM Tris-HCl pH 8.25, 30 °C, 10 min). The 
excitation λ = 355 nm was used instead of the typical λ = 340 nm due to the available 
equipment filter selection. Assays were preformed utilizing the FLOUstar Omega plate 
reader (BMG LABTECH) and nontreated white optical flat bottom nonsterile 96-well 
plates (Nunc). The reactions were initiated by addition of 0.25, 1, 5, or 10 µM wild-type 
or mutant MtmOIV. To determine the value of NADPH oxidation a standard curve was 
created utilizing known concentrations of NADPH. Kinetic parameters were determined 
by fitting with Kaleidagraph 4.0 (Synergy) 
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Mutagenesis Primers 
R169A forward 5' -GCG ACG GCG GGG CCA GCA CGG TGC- 3' 
R169A reverse 5' -GCA CCG TGC TGG CCC CGC CGT CGC- 3' 
R173A forward 5' -GCAGCA CGG TGG CGC CGC GGC TGG CCG- 3' 
R173A reverse 5' -CGG CCA GCC GCG CCA CCG TGC TGC- 3' 
P84A forward 5' -CCA AGG GGC TGG CCT TCG CCG GG-3' 
P84A reverse 5' -CCC GGC GAA GGC CAG CCC CTT GG- 3' 
F89A forward 5' -CTT CGC CGG GAT CGC CAC CCA GGG CTT G- 3' 
F89A reverse 5' -CAG GCC CTG GGT GCC GAT CCC GGG GAA G-3' 
R204A forward 5' -GAG GTG CCG CGC GCC TGG GAG CGC AC- 3' 
R204A reverse 5' -GTG CGC TCC CAG GCG CGC GGC ACC TC-5' 
H50A forward 5' -ACG CCG TCG GCG CCG ACC GGG CGG-3' 
H50A reverse 5' -CCG CCC GGT CGG CGC CGA CGG GCT-3' 
D51A forward 5' -GTC GGC CAC GCC CGG GCG GGG- 3' 
D51A reverse 5' -CCC CGC CCG GGC GTG GCC GAC- 3' 
W205A forward 5' -TGC CGC GCC GCG CGG AGC GCA CCC- 3' 
W205A reverse 5' -GGG TGC GCT CCG CGC GGC GCG GCA- 3' 
R225A forward 5' -GCG GCC TTG GGG CCG GGT GGT CG-3' 
R225A reverse 5' -CGA CCA CCC GGC CCC AAG GCC GC- 3' 
2.6 Reflections and Future Directions 
If the experiments preformed in this chapter were to be repeated several changes 
could be made to improve the validity of the findings presented. One major change would 
be to perform all the kinetic analysis using the fluorescence based method used when 
studying MtmOIV’s NADPH binding dicussed in section 2.5.5 This would allow the 
experimenter to use a much higher concentration of NADPH when studying PreB binding 
and produce more universally accepted KM values so that MtmOIV’s catalytic efficiency 
could be compared to other enzymes and not just between wildtype and the generated 
mutants. Another point of improvement would be to monitor the uncoupling of PreB 
turnover from NADPH oxidation. This could be accomplished my monitoring the 
Table 3. Mutagenesis primrs 
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creation of hydrogen peroxide generated when uncoupling in present using one of the 
many commercially available horseradish peroxidase assays. A third point of 
improvement entails verifying that the mutations introduced into MtmOIV’s amino acid 
sequence are not disrupting then enzymes overall structure. One crude way to perform 
this analysis would be to utilize circular dichroism to compare the specta of mutant 
enzymes to the wildtype enzyme. This would be a fast and inexpensive way to verify the 
mutant enzymes were folded correctly and that the overall tertiary structure was 
undisrupted. A second more thorough approach to this problem would be to crystallize 
and solve the X-ray crystal structure of each generated mutant with substrate. In addition 
to ensuring the overall structure of the enzyme was intact, an intricate view of what 
interactions each mutation may be disrupting would be gained. However, this method 
would be relatively expensive and very time consuming.  
The next major step in this project would be to obtain soluble purified MtmW 
enzyme to confirm the existence of the theorized codependence between MtmOIV and 
MtmW. Though production of soluble MtmW has been attempted numerous times it has 
yet to be successfully obtained. If one were to continue this project, expression of MtmW 
in Streptomyces using vector pXY200 is a promising approach to accomplishing this 
task. Table 4 lists unsuccessful attempts at producing soluble MtmW. Additionally, the 
plasmid maps associated with these attempts are shown in the appendix of this 
dissertation. 
Expression Construct Organism  Inclusion Bodies 
1 MtmW-Pet28a- N His6x E. coli Yes 
2 MtmW-Pet28a- C His6x E. coli Yes 
3 MtmW codon optimized- Pet28a- N His6x E. coli Yes 
4 MtmW codon optimized- Pet28a- C His6x E. coli Yes 
5 MtmW-PetSUMO- N His6x E. coli Yes 
6 MtmW-PetNusA- N His6x E. coli Yes 
*Varying IPTG concentrations and induction temperature were attempted for each
construct. Refolding of inclusion bodies was also attempted in L-arginine rich buffer. 
Table 4. MtmW Expression Constructs 
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3 Role of the Synergistic Reductive O-Methyltransferase GilM of the Gilvocarcin 
Biosynthetic Pathway and Investigation of Enzyme-Enzyme Interactions with its 
Co-dependent Partner GilR.  
3.1 Abstract  
GilM an enzyme from the gilvocarcin biosynthetic pathway with an unknown 
function was investigated in vitro utilizing purified recombinant enzymes and a 
synthetically prepared pathway intermediate. This study reveals GilM as a key enzyme of 
the gilvocarcin pathway exhibiting dual functionality as a reductase and O-
methyltransferase responsible for both the reduction of a quinone intermediate to a 
hydroquinone and the associated stabilizing O-methylation and hemiacetal formation. 
Additionally, GilM was found to mediate its reductive catalysis through the assistance of 
GilR. GilR provides its bicovalently bound FADH2 cofactor for the GilM reaction. In 
turn GilM regenerates FAD for GilR’s next catalytic cycle establishing a unique co-
dependent relationship. This unusual synergy eventually completes the biosynthesis of 
the polyketide-derived defuco-gilvocarcin chromophore. Additionally, the necessary 
enzyme-enzyme interaction between GilM and GilR was probed revealing the absence of 
a long-lived interface between the two, alluding to a transient relationship during 
catalysis.  
Figure 27. Overall representation of the co-dependent GilR-GilM catalytic 
cascade. 
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3.2 Introduction 
The gilvocarcins belong to the angucycline group of natural products. 
Angucylines are the largest group of polyketide-derived natural products and are rich in 
biological activities and interesting chemical scaffolds. The unique oxidative scaffold 
rearrangements and other post-PKS tailoring events were what first attracted researchers 
to the group.94 The gilvocarcin family of angucyclines were originally discovered in the 
mid-1950s.95 However, their structures were not solved until 1981 when X-ray 
structure96,97 was able to determine relative conformation of gilvocarcin M, leading to the 
structural elucidation of other group members.97–100 The key characteristic of the 
gilvocarcin family is the polyketide-derived benzo[d]naphtho[1,2-b]pyran-6-one 
chromophore and variable C-glycosidically linked sugar moiety.101–105 Gilvocarcins are 
known for their strong antitumor activities, low toxicities, and unique mode of 
action.99,103,106 The benzo[d]naphtho[1,2-b]pyran-6-one core’s  8-vinyl side chain 
undergoes photoactivated [2+2]-cycloaddition with DNA’s thymine bases under 
irradiating conditions with low energy UV or visible light.107–109 Additionally, the sugar 
moiety is essential for observed gilvocarcin-mediated cross-linking of histone H3 or heat 
shock protein GRP78 with DNA resulting in the disruption of DNA replication and 
transcription.110 In addition to anticancer activity gilvocarcins exhibit strong 
antibacterial95 and antiviral properties.111 In spite of these many positive properties, poor 
solubility remains a major impediment toward development into useful therapeutics.112,113 
The aromatic core of the gilvocarcins is produced by a type II polyketide synthase 
(PKS),114,115 initially yielding an angucycline biosynthetic intermediate (e.g., 3 in figure 
26). Oxidative post-PKS modifications convert this intermediate into the unique defuco-
gilvocarcin chromophore.116 The role of many of the gilvocarcin post-PKS tailoring gene 
products were assigned based on gene inactivation, cross-feeding and labeling 
studies.36,114–119 In fact most of the genes of the three known biosynthetic clusters120 of 
this group have been assigned to certain enzymatic activities with gilM (encoding an 
enzyme of unknown function) being one of a few a notable exceptions as this gene did 
not bare high sequence similarity to other know sequences. Thus, the function of its gene 
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product remained obscure despite appearing to be crucial for the biosynthesis of 
gilvocarcin, as mutant strains created by deletion of this individual gene did not 
accumulate any isolable metabolites. Here we report the assignment of the GilM enzyme 
as a dual function reductase and O-methyltransferase responsible for both the reduction 
of a quinone intermediate to a hydroquinone and the associated stabilizing O-methylation 
and hemiacetal formation. It was also discovered that GilM requires the assistance of 
oxidoreductase GilR to mediate its reductive functionality. GilR provides its bicovalently 
bound FADH2 cofactor for the GilM reaction. In turn, GilM regenerates FAD for GilR’s 
next catalytic cycle establishing a unique co-dependent relationship. This unusual 
synergy eventually completes the biosynthesis of the polyketide-derived defuco-
gilvocarcin chromophore. Additionally, the proposed enzyme-enzyme interaction 
between GilM and GilR was investigated and did not reveal a prolonged interaction 
between the two, thus indicating their co-dependent relationship may be transient in 
nature.  
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Figure 28. Key oxidative rearrangement and follow-up sequence of events 
involving GilM and GilR reactions en route to defuco-gilvocarcin M (7). 
60	  
3.3 Results and Discussion 
3.3.1 Determing GilM’s Catalytic Activity 
BLAST analysis121,122 revealed GilM to have low similarity (34-37% sequence 
identity) to nucleotidyl-S-transferases, such as thiopurine-S-methyltransferases from 
Rhodococcus equi or Mycobacterium avium, and benzoquinone methyltransferases from 
Mycobacterium tuberculosis (33% sequence identity). The conceptual translated amino 
acid sequence of GilM contains the amino acid sequence VLDLGCGLG at position 49-
57, which is predicted to be a SAM binding motif following the general pattern 
Figure 29.	  HPLC traces of the enzymatic reactions with 5. (A) Standard 5; (B) 5 
+ GilM + SAM + 5 min; (C) 5 + GilM + SAM + 10 min; (D) 5 + GilM + SAM + 
15 min; (E) intermediate 8 isolated from HPLC (mixture of closed and open 
form); (F) 8 + GilM. 
8 6 
5 
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hh(D/E)hGXGXG (where h represents a hydrophobic residue). To determine the function 
of GilM compound 5 was chemoenzymatically produced by co-worker Nidhi Tibrewal 
and used as substrate. This reaction accumulated compound 6 proving GilM was 
responsible for quinone reduction, hemiacetal formation, and O-methylation (figure 27, 
trace D). Surprisingly, the GilM reaction seemed to be able convert 5 to 6 even in 
absence of SAM, which prompted further investigation of GilM for any bound SAM 
cofactor. 
 To further analyze the reaction sequence catalyzed by GilM, compound 5 was 
incubated with GilM and the reaction was studied at different time points (Figure 27). 
With stoichiometric enzyme quantities, the substrate was 80% converted into the product 
after 15 min (Figure 27, trace D). When the reaction was analyzed by reversed phase 
HPLC-MS in 3–5 min intervals, a new peak (16) appeared with shorter retention time 
than the overall product 6 (Figure 27). Although NMR analysis of 8 was impossible due 
to its instability, LC-MS analysis suggested it to be demethyl-defuco-pregilvocarcin M 
(m/z 323 [M – H]−). To prove that 8 was an intermediate en route to 6 and not a shunt 
product, 8 was incubated with GilM, and, as anticipated, was rapidly converted to 6 
(Figure 27, trace F). Overall, the results show that GilM catalyzes a sequence of 
reactions: (i) quinone reduction, (ii) hemiacetal formation and (iii) O-methylation, to 
construct the tetracyclic core of the gilvocarcins.  
 3.3.2 Identification of GilM’s SAM cofactor 
GilM catalyzes reductive O-methylation without the addition of any external 
cofactor. However, the BLAST analysis showed a very vague similarity to thiopurine-S-
methyltransferases as previously discussed. To analyze any bound cofactor, the enzyme 
was boiled for 5 minutes and centrifuged (12000 ×g, 5 min). The supernatant was then 
subjected to LC-MS analysis. A linear gradient of acetonitrile and 0.1% formic acid-
water (solvent A = 0.1% formic acid-H2O; solvent B = acetonitrile; 0-15 min 25% B to 
100% B; 16-24 min 100% B; 25-26 min 100% to 25% B; 27-29 min 25% B) with flow 
rate of 0.5 mL/min was used to separate the compounds in a Waters Symmetry C18 (4.6 × 
250 mm, 5 µm) column. The supernatant showed UV-absorption at λ=260 nm, typical of 
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an adenosine spectrum, indicating co-purified SAM. To further verify presence of loosely 
bound S-adenosyl methionine, a standard solution of S-adenosyl methionine was prepared 
in 50 mM phosphate buffer and was used in parallel for comparison. GilM was found to 
be co-purifying with S-adenosyl methionine (Figure 28). 
 
 
 
 
 
 
 
 
Figure 30. HPLC traces of the released cofactor: (A) standard S-adenosyl 
methionine; (B) Cofactor released from GilM; (C) S-adenosyl methionine boiled 
for 5 min. 
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Figure 32. HPLC traces of the enzymatic reactions with 5: (A) standard 5; (B) 
standard defuco-gilvocarcin M (45); (C) 5 + GilM; (D) 5 + GilM + GilR; (E) 5 
+ GilM + GilR + SAM. 
Figure 31. R and M genes in gilvocarcin (gil), ravidomycin (rav) and chrysomycin 
(chry) gene clusters. 
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3.3.3 Co-dependence between GilM and GilR 
One remaining question was how the regeneration of GilM occurred after the 
reduction of the quinone. Interestingly, the homologous GilM-activity from the 
biosynthetic pathways of other structurally similar compounds, chrysomycin A (chry) 
and ravidomycin V (rav), is encoded on the same gene as the oxidoreductase GilR-
activity,120 while in the gilvocarcin pathway, gilM and gilR are encoded by two separate 
genes (Figure 29).114 This prompted the proposal that GilM could be working in 
conjunction with GilR, an FAD dependent oxidoreductase that catalyzes the very last step 
in gilvocarcin biosynthesis by converting pregilvocarcin to gilvocarcin. Additionally, 
GilR was shown to be able to convert sugar free defuco-pregilvocarcins.37,119 We 
hypothesized that GilM utilizes the reduced flavin generated in the GilR reaction to 
reduce the quinone thereby regenerating oxidized flavin for the next catalytic cycle. To 
validate this hypothesis, compound 5 was incubated with GilM and GilR (Figure 30). The 
assistance of GilR for the reducing capability of GilM was established by measuring the 
amount of product formed during the reactions. Catalytic amounts of GilM alone mainly 
accumulated starting material with a minor production of 6 (Figure 30, trace C). In the 
absence of SAM, GilM and GilR accumulated a new peak (Figure 30, trace D) that 
corresponds to demethyl-defuco-gilvocarcin M123 (9, m/z 321 [M-H]−). Adding SAM to 
the GilM-GilR reaction mixture led to the accumulation of 10 (Figure 2.5, trace E). A 10-
fold increase in the formation of 10 in the GilM-GilR reaction versus using GilM alone 
confirms that GilM works synergistically with GilR.  
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3.3.4 Investigating GilM-GilR Enzyme-Enzyme Interactions 
GilM’s synergistic activity with GilR necessitates the presence of an intimate 
enzyme-enzyme interface as the shared FAD cofactor is known to be bicovalently bound 
to GilR.37 To investigate this enzyme-enzyme interaction two experiments were 
preformed to test it stability. First, equal amounts of heterologously expressed and 
purified GilM and GilR were mixed, incubated at room temperature for 10 minutes, and 
then subjected to native polyacrylamide gel electrophoreses (PAGE). When compared to 
controls of GilR and GilM alone, the enzyme mixture did not appear to form a stable 
complex as no new bands indicating complex formation where see in the native PAGE 
results (figure 31).  
To confirm this finding was not due to the limitations of the native PAGE 
technique a second study was conducted utilizing size exclusion fast protein liquid 
chromatography (FPLC). When equal amounts of GilM and GilR where mixed in the 
presence of SAM and subjected to FPLC purification and the FPLC chromatogram of the 
GilM-GilR mixture was compared to the FPLC chromatograms of either enzyme alone 
no evidence of a GilM-GilR complex was seen (figure 32). The lack of evidence of 
complex formation in both native PAGE and FPLC enzyme interaction studies combined 
with the knowledge that GilM and GilR must cooperate suggests that the GilM-GilR 
GilM GilM + GilR GilR 
Figure 33. Native PAGE probing for GilM-GilR enzyme-enzyme interaction.  
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interaction is transient in nature or requires different condition to initiate and/or stabilize 
complex formation.  
 
 
 
 
 
 
 
Figure 34. FPLC chromatograms of GilM+GilR (blue), GilM (red), and GilM 
(green).  
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3.4 Conclusions 
The gene product of GilM from the gilvocarcin biosynthetic gene cluster was 
identified via in vitro characterization as a SAM-dependent multifunctional enzyme 
responsible for the reduction of a quinone intermediate to a hydroquinone and the 
associated stabilizing O-methylation and hemiacetal formation. This enzyme is one of 
only a limited number of bifunctional post-PKS tailoring enzymes identified to date as 
discussed in Chapter 1. In addition to being identified as a bifunctional enzyme, GilM 
was also identified as a co-dependent enzyme requiring the assistance of the 
oxidoreductase GilR to function. GilM is hypothesized to utilize GilR’s bicovalently 
bound reduced flavin generated in the GilR reaction for quinone reduction thereby 
regenerating oxidized flavin for the next catalytic cycle. To further interrogate the GilM-
GilR relationship two different enzyme-enzyme interaction studies were conducted. 
These studies led to the conclusion that the GilM-GilR interaction is transient as no 
enzyme complex was detected in either case. The identification of GilM’s catalytic 
functionality and its co-dependent relationship with GilR elucidates the end of the 
gilvocarcin biosynthetic pathway and establishes the groundwork for future 
combinatorial biosynthetic work that may lead to the production of new gilvocarcin 
analogues with improved druggability. Further investigation of the GilM-GilR interaction 
is needed to fully understand the complexity of their relationship. The X-ray crystal 
structure of GilR has previously been solved and the crystallization and structure 
elucidation of GilM has been commenced. Once GilM’s structure has been solved 
docking studies or even co-crystallization of both enzymes may reveal more details about 
this curious transient relationship.  
3.5 Methods 
3.5.1 Cloning of GilM and GilR 
For GilR pfu-polymerase (Stratagene) was used to amplify the ~1.5 kb nucleotide 
sequence of gilR from the cosmid G9B3 using the respective set of primers GilR_for:  5’-
CGCCATATGACCGCTTCCGTACCGCCGTTCACGGTG-3’, and GilR_rev:  5’-
CCAGAATTCTCAGAGTCCTATGGACATGCTGTG-3’). The generated PCR product 
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was cloned into Zero Blunt® TOPO® vector (Invitrogen), and the positive clones were 
sequenced to make sure that no mutation had been incorporated during amplification. 
GilR was recovered as an NdeI-EcoRI fragment from the TOPO-GilR construct and 
ligated at the identical sites of pET28a(+) (Novagen)  to generate a GilR expression 
construct.  
 For GilM pfu-polymerase (Stratagene) was used to amplify the ~800 bp 
nucleotide sequence of gilM from the cosmid G9B3 using the respective set of primers 
GilM_for:  5’-CGCCATATGCCAACGGGCAGCACG -3’; and GilM_rev:  5’-
CCAGAAATCGGAGAGCCCGGCATGA -3’). The generated PCR product was cloned 
into Zero Blunt® TOPO® vector (Invitrogen), and the positive clones were sequenced to 
make sure that no mutation had been incorporated during amplification. GilM was 
recovered as an NdeI-EcoRI fragment from the TOPO-GilM construct and ligated at the 
identical sites of pET28a(+) (Novagen)  to generate a GilM expression construct.  
3.5.2 Expression and Purification of Enzymes 
gilM and gilR genes were expressed using pET28a(+) expression constructs in E. 
coli BL21 (DE3) with a 6x N-terminal polyhistidine tag. A single colony was transferred 
to 10 mL LB supplemented with 50 µg/mL kanamycin and grown at 37 °C and 250 rpm 
for 12 h. Subsequently, 500 mL LB supplemented with 50 µg/mL kanamycin was 
inoculated with 5 mL of the culture and was grown at 37 °C until OD600 reached to 0.5. 
Gene expression was induced with isopropyl-β-D-1-thiogalactopyranoside (IPTG, 0.2 
mM final concentration) and the culture was allowed to grow at 18 °C for 16 h. The cell 
pellets were collected by centrifugation (4000 × g, 15 min) and were washed twice with 
20 mL of lysis buffer (50 mM KH2PO4, 300 mM KCl, 10 mM imidazole, pH 8.0). The 
cells were lysed using a French Press and the crude soluble enzyme fractions were 
collected through centrifugation (16000 × g, 1h). The crude enzymes were loaded onto a 
Talon metal affinity resin (BD Biosciences) column and were washed three times with 
lysis buffer. The enzymes were then eluted with elution buffer (50 mM KH2PO4, 300 
mM KCl, 250 mM imidazole, pH 8.0). The purified proteins were concentrated using an 
Amicon Ultra centrifugal filter (Millipore Corp.) and stored as 25% glycerol stocks at -20 
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°C. The concentration of protein was determined by the Bradford method using a 
calibration curve from known concentrations of BSA.  
3.5.3 Cofactor Analysis of GilM 
GilM catalyzes reductive methylation without any external cofactor. However, the 
BLAST analysis showed a very vague similarity to thiopurine-S-Methyltransferase. To 
analyze any co-purified cofactor, the enzyme was boiled for 5 minutes and centrifuged 
(12000 ×g, 5 min). The supernatant was then subjected to LC-MS analysis. A linear 
gradient of acetonitrile and 0.1% formic acid-water (solvent A = 0.1% formic acid-H2O; 
solvent B = acetonitrile; 0-15 min 25% B to 100% B; 16-24 min 100% B; 25-26 min 
100% to 25% B; 27-29 min 25% B) with flow rate of 0.5 mL/min was used to separate 
the compounds in a Waters Symmetry C18 (4.6 × 250 mm, 5µm) column. The supernatant 
showed UV-absorption at λ=260nm, typical of adenosine spectrum. To further verify 
presence of loosely bound S-adenosyl methionine a standard solution of S-adenosyl 
methionine was prepared in 50 mM phosphate buffer and was used in parallel for 
comparison. GilM was found to be co-purifying with S-adenosyl methionine. 
3.5.4 GilM Kinetic Profile 
A typical reaction mixture (50 µM) composed of substrate (92), 50 mM phosphate 
buffer, 20 µM enzyme (final concentration) was incubated at 25 °C. After 5 min reaction 
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Figure 35. GilM kinetic profile with substrate 5.  
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was extracted twice with EtOAc (300 µl) and combined organic layers were dried under 
vacuum. The residue was then dissolved in 50 µl acetonitrile and 20 µl was injected onto 
HPLC following the protocol described in Section 3.5.3. The amount of product formed 
was estimated by plotting the peak area in a standard calibration curve. The data resulting 
from incubating seven different substrate concentrations with enzyme were fit to the 
Michael-Menten equation with nonlinear regression. kcat and KM values were calculated 
using GraphPad Prism 5.0. The analysis was done in triplicate and the average was taken. 
The analysis yielded a kcat of 0.02930 min-1 and a KM of 35.38 µM.	  	  
3.5.5 GilM-GilR Intraction Native PAGE Analysis 
A 10% native PAGE gel was prepared by combining 3.4 mL acrylamide/bis-
acrylamide (30%/0.8% w/v), 6.49 mL 0.375 M tris-HCl (pH 8.8), 100 µl 10% ammonium 
persulfate (w/v), and 10 µl TEMED in a 15 mL falcon tube and mixing by inversion. This 
solution was then quickly pipetted into the glass gel casting apparatus until 3/4 full. The 
separating gel was the allowed to gelate for 30 minutes. Next, the stacking gel solution 
was prepared by combining 4.275 ml 0.375 M tris-HCl (pH 8.8), 0.67 mL   
acrylamide/bis-acrylamide (30%/0.8% w/v), 0.05 mL 10% ammonium persulfate (w/v), 
and 5 µl TEMED in a 15 mL falcon tube and mixing by inversion. The stacking gel 
solution was pipetted on top of the separating gel, a comb was inserted and the solution 
was allowed to gelate for 30 minutes.  
10 µl of each protein sample was then mixed with 10 ul sample buffer composed 
of 62.5 mM Tris-HCl (pH 6.8), 25% glycerol, and 1% bromophenol blue. The samples 
were loaded onto the native gel and electrophoresed for 1.5 hours at 150 volts. The gel 
was carefully removed from between the glass plates of the gel cast and stained in 
coomassie blue staining solution (0.3% coomassie brilliant blue R-250 w/v, 45% 
methanol v/v, 10% glacial acetic acid v/v, 45% distilled water v/v) for 45 minutes. 
Finally, the gel was rinsed with distilled water and destained in destaining solution (20% 
methanol v/v, 10% glacial acetic acid v/v, 70% distilled water v/v) overnight. 
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3.5.6 GilM-GilR Interaction FPLC Analysis 
GilR and GilM were first purified using the method discussed in section 3.5.2 
with the exception of using different lysis, wash, and elution buffers. The cell lysis buffer 
was composed of 40 mM Tris pH 8.0, 400 mM NaCl, 10% glycerol (w/w), and 2 mM  β-
mercaptoethanol. The wash buffer was composed of 40mM Tris pH 8.0, 400mM NaCl, 
10% glycerol (w/w), 2mM  β-mercaptoethanol, and 20mM imidazole. The elution buffer 
was composed of 40mM Tris pH 8.0, 400mM NaCl, 10% glycerol (w/w), 2mM  β-
mercaptoethanol, and 200mM imidazole. Each protein stock solution was diluted to a 
concentration of 1mg/ml using 40 mM Tris-HCl pH 8.0, 100 mM NaCl, and 2mM  β-
mercaptoethanol.  25µl of 1mg/ml GilM was mixed with 72µl of 40mM Tris-HCl pH 8.0, 
100 mM NaCl, and 2mM β-mercaptoethanol. 3µl of 50mM SAM prepared in DMSO was 
then added to the solution followed by the addition of 25µl of GilR 1mg/ml stock. The 
enzyme mixture was passed through a size-exclusion S-200 column equilibrated in 40 
mM Tris-HCl pH 8.0, 100mM NaCl, and 2mM  β-mercaptoethanol using the Bio-Rad 
BioLogic DuoFlow system.	   Controls of GilM and GilR alone were then run for 
comparison of the chromatograms.	  	  
3.6 Reflections and Future Directions 
If the experiments preformed in this chapter were to be repeated several changes 
could be made to improve the validity of the findings presented. One major change would 
be to use C-terminally histagged GilM during all experimentation. During initial 
crystallization screening it was found that a C-terminally histagged GilM expression 
construct (GilM-Pet22b(+)-C His6x shown in the appendix) produced greater yields of 
soluble GilM protein. Additionally, it was found that C-terminally histagged GilM was 
more stable then N-terminally histagged GilM. It should also be noted that upon removal 
of either the N or C terminal histag GilM rapidly precipitates. Another major 
improvement would be to change the method of GilM reaction monitoring with regard to 
kinetic analysis. Rather then monitoring the less stable GilM products it would be better 
to include a large quantity of GilR and monitor the formation of the final stable product 
defuco-gilvocarcin M.  
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The next major steps in this project include verification of transient protein-
protein interactions between GilM and GilR and structural elucidation of GilR. Either an 
E. coli based two-hybrid assay or an alpha screen could be used to positively identify the 
presence of a transient protein-protein interaction. Another method of verification could 
be obtained by solving the X-ray crystal structures of GilM and a fusion homologue, such 
as RavRM or ChryRM. The structure of GilM could then be computationally docked to 
the previously solved structure of GilR using the structure of the fusion homologue as a 
guide.  
Portions of this chapter have been reproduced with permission from the following 
publication: copyright ACS publications 
Tibrewal, N.*, Downey, T. E.+, Van Lanen, S. G., Ul Sharif, E., O'Doherty, G. A., Rohr, 
J. "Roles of the Synergistic Reductive O-Methyltransferase GilM and of O-
Methyltransferase GilMT in the Gilvocarcin Biosynthetic Pathway." J. Am. Chem. Soc., 
2012, 134, 12402–12407. 
*Chemoenzymatic synthesis of substrate 5, GilM reaction analysis, and collection of
kinetic data. 
+  Kinetic assay development, analysis of kinetic GilM kinetic data, construction of GilM-
Pet28a vector for enzyme-enzyme interaction studies, native PAGE analysis, and FPLC 
method development and analysis. 
Copyright © Theresa Downey 2014 
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4 Summary 
Post-PKS tailoring enzymes offer a unique opportunity to biosynthetically 
engineer new molecules for medicinal and industrial applications. If scientists are to fully 
exploit their potential the structures and functions of these enzymes must be studied in 
detail not only as lone entities, but also synergistically as co-dependent partners. For both 
bifunctional and co-dependent post-PKS enzymes there is a need for more functional and 
structural information. Through the work presented in this dissertation a better understand 
of the enzyme MtmOIV, of the MtmOIV-MtmW co-dependent enzyme pair from the 
mithramycin biosynthetic pathway, and the enzyme GilM, a bifunctional partner of the 
GilM-GilR co-dependent enzyme pair from the gilvocarcin biosynthetic pathway, has 
been gained.  
Our new refined MtmOIV structure is the first substrate-bound crystal structure of 
MtmOIV. The MtmOIV structure with its bound substrate PMB revealed significant 
differences to the previous computer model, in which PMB was docked into the low 
resolution structure of MtmOIV. The new MtmOIV protein structures revealed that a 
tryptophan (W205), arginine (R204) residue and a phenylalanine (F89) residue play key 
roles in guarding the entry loop during the substrate binding process. These new 
structures also show that a histidine (H50) and an aspartate (D51) residue seem to be 
important to fine-tune the positioning of the FAD cofactor. Additionally, two glutamine 
residues (Q78 and Q91) and a proline residue (P84) were recognized as critical to holding 
the substrate’s trisaccharide chain, essential for anticancer activity,78,79 in place. These 
three trisaccharide stabilizing residues were not identified in the previous PMB–MtmOIV 
binding site model but are likely critical for our future attempts to further modify MTM’s 
trisaccharide side chain through enzyme engineering. Furthermore, using a low-
resolution complex structure of MtmOIV in complex with NADPH combined with site 
directed mutagenesis studies, four arginine residues (R169, R173, R174, R277) important 
for binding NADPH were identified and confirmed.44 With this new structural 
information it may be possible to design a more promiscuous MtmOIV enzyme capable 
of creating new and improved mithramycin analogues.  
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GilM from the gilvocarcin biosynthetic gene cluster was identified via in vitro 
characterization as a SAM-dependent multifunctional enzyme responsible for both the 
reduction of a quinone intermediate to a hydroquinone and the associated stabilizing O-
methylation and hemiacetal formation. This enzyme is one of only a limited number of 
bifunctional post-PKS tailoring enzymes identified to date. In addition to being identified 
as a bifunctional enzyme GilM, was identified as a co-dependent enzyme requiring the 
assistance of the oxidoreductase GilR to function. GilM is hypothesized to utilize GilR’s 
bicovalently bound reduced flavin generated in the GilR reaction for quinone reduction 
thereby regenerating oxidized flavin for the next catalytic cycle. To further interrogate 
the GilM-GilR relationship, enzyme-enzyme interaction studies were conducted. These 
studies led to the conclusion that the GilM-GilR interaction is transient as no enzyme 
complex was detected in either case. The identification of GilM’s catalytic functionality 
and co-dependent relationship with GilR elucidates the end of the gilvocarcin 
biosynthetic pathway and establishes the groundwork for future combinatorial 
biosynthetic work that may lead to the production of new gilvocarcin analogues with 
improved druggability.  
Copyright © Theresa Downey 2014 
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5 Appendix 
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5.2 MtmOIV  
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5.2.2 MtmOIV Gene Sequence  
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5.2.3 Pet28a(+) Expressed MtmOIV Enzyme Seqeunce  
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5.3 MtmW 
5.3.1 MtmW-Pet28a-N His6x 
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5.3.2 MtmW-Pet28a-C His6x 
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5.3.3 MtmW-PetNusA-N His6x 
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5.3.4 MtmW-PetSUMO-N His6x 
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5.3.5 MtmW Gene Sequence 
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5.3.6 Codon optimized MtmW Gene Sequence 
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5.4 GilM  
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5.4.2 GilM Gene Sequence  
	  
 
5.4.3 Pet28a(+) Expressed GilM Enzyme Sequence 
	  
 
 
87	  
5.4.4 GilM-Pet22b(+) Plasmid Map 
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5.5 GilR  
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Publications: 
Molecular insight into substrate recognition and catalysis in the Baeyer-Villiger 
monooxygenase MtmOIV, the key frame modifying enzyme in the biosynthesis of 
anticancer agent mithramycin. 
Downey T, Bosserman MA, Noinaj N, Buchanan SK, Rohr J. 
ACS Chem Biol. 2013 Sep 13. [Epub ahead of print] 
Baeyer-Villiger monooxygenases (BVMOs) have been shown to play key roles for the 
biosynthesis of important natural products. MtmOIV, a homodimeric FAD- and NADPH-
dependent BVMO, catalyzes the key frame-modifying steps of the mithramycin 
biosynthetic pathway, including an oxidative C-C bond cleavage, by converting its 
natural substrate premithramycin B into mithramycin DK, the immediate precursor of 
mithramycin. The drastically improved protein structure of MtmOIV along with the high-
resolution structure of MtmOIV in complex with its natural substrate premithramycin B 
are reported here, revealing previously undetected key residues that are important for 
substrate recognition and catalysis. Kinetic analyses of selected mutants allowed us to 
probe the substrate binding pocket of MtmOIV, and also to discover the putative NADPH 
binding site. This is the first substrate-bound structure of MtmOIV providing new 
insights into substrate recognition and catalysis, which paves the way for the future 
design of a tailored enzyme for the chemo- enzymatic preparation of novel mithramycin 
analogues. 
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Roles of the synergistic reductive O-methyltransferase GilM and of O-
methyltransferase GilMT in the gilvocarcin biosynthetic pathway. 
Tibrewal N, Downey TE, Van Lanen SG, Ul Sharif E, O'Doherty GA, Rohr J. 
J Am Chem Soc. 2012 Aug 1;134(30):12402-5. doi: 10.1021/ja305113d. 
Two enzymes of the gilvocarcin biosynthetic pathway, GilMT and GilM, with unclear 
functions were investigated by in vitro studies using purified, recombinant enzymes along 
with synthetically prepared intermediates. The studies revealed GilMT as a typical S-
adenosylmethionine (SAM) dependent O-methyltransferase, but GilM was identified as a 
pivotal enzyme in the pathway that exhibits dual functionality in that it catalyzes a 
reduction of a quinone intermediate to a hydroquinone, which goes hand-in-hand with a 
stabilizing O-methylation and a hemiacetal formation. GilM mediates its reductive 
catalysis through the aid of GilR that provides FADH(2) for the GilM reaction, through 
which FAD is regenerated for the next catalytic cycle. This unusual synergy eventually 
completes the biosynthesis of the polyketide-derived defuco-gilvocarcin chromphore. 
Baeyer-villiger C-C bond cleavage reaction in gilvocarcin and jadomycin 
biosynthesis. 
Tibrewal N, Pahari P, Wang G, Kharel MK, Morris C, Downey T, Hou Y, Bugni TS, 
Rohr J. 
J Am Chem Soc. 2012 Nov 7;134(44):18181-4. doi: 10.1021/ja3081154. 
GilOII  has  been  unambiguously  identified  as  the  key  enzyme  performing  the  
crucial  C-C  bond cleavage reaction responsible for the unique rearrangement of a 
benz[a]anthracene skeleton to the benzo[d]naphthopyranone backbone typical of the 
gilvocarcin-type natural anticancer antibiotics. Further investigations of this enzyme led 
to the isolation of a hydroxyoxepinone intermediate, leading to important conclusions 
regarding the cleavage mechanism. 
